Università degli Studi di Ferrara

DOTTORATO DI RICERCA IN "FARMACOLOGIA E ONCOLOGIA MOLECOLARE"

CICLO XXVI

COORDINATORE Prof. Antonio Cuneo

Endogenous kynurenic acid modulates extracellular glutamate and GABA levels in the rat prefrontal cortex and striatum: *in vivo* microdialysis studies

Settore Scientifico Disciplinare BIO/14

Dottorando	**Tutore**
Dott. Beggiato Sarah	Prof. Ferraro Luca
_____	_____

Anni 2010/2013

Ai miei genitori e a mio nonno!!!

I hope u forgive me for not being able

to have come say goodbye to you…

"Never Give Up, Just Follow Your Dreams...."

Sarah

INDEX

ABBREVIATIONS

α7nAChR: α7 nicotinic acetylcholine receptor;

AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;

CNS: central nervous system;

CSF: cerebrospinal fluid;

ESBA: (S)-4-ethylsul-fonylbenzoylalanine;

GABA: γ-aminobutyric acid;

3-HANA: 3-hydroxyanthranilic acid;

3-HK: 3-hydroxy-L-kynurenine;

IDO: indoleamine 2,3-dioxygenase;

KAT: kynurenine aminotransferase;

KMO: kynurenine 3-monoxygenase;

KP: kynurenine pathway;

KYNA: kynurenic acid;

NMDAR: N-methyl-D-aspartate receptor;

PFC: prefrontal cortex;

PV: parvalbumin;

QUIN: quinolinic acid;

SN: substantia nigra;

SZ: schizophrenia;

TDO: tryptophan 2,3-dioxygenase;

1. INTRODUCTION

"We believe that interventions aimed specifically at reducing the level of kynurenic acid in the brain are a promising strategy for cognitive improvement in both healthy individuals and in those suffering from a variety of brain diseases ranging from schizophrenia to Alzheimer's disease," Dr. R. Schwarcz.

Prof. Robert Schwarcz

Kynurenic acid (KYNA) was discovered in 1853 by the German chemist Justus von Liebig in dog urine. It was the firstly identified component of the family of "kynurenines", a group of metabolically related compounds which are derived from the essential amino acid tryptophan. In mammals, the diet represents the main source of tryptophan and the amino acid is metabolized via the so-called kynurenine pathway (KP). Recently, it has been demonstrated that a dysfunction of this pathway is associated with neurodegenerative and other neurological disorders, including psychiatric diseases such as schizophrenia (SZ, Figure 1). In particular, it has been demonstrated that fluctuations in the levels of kynurenines showed discrete effects on the nervous system and immune system (Schwarcz,

2004). Specifically, KYNA levels are elevated in the prefrontal cortex (PFC) of individuals with SZ, and normalization of KYNA concentrations in the brain has been suggested as an effective treatment strategy for alleviating cognitive deficits in this mental illness.

In this dissertation, the effects of KYNA on extracellular GABA and glutamate levels in the rat striatum and prefrontal cortex (PFC), will be described. Although the obtained results might be also involved in the neuroprotective action of KYNA, their possible relevance in the ethiopathogenesis of SZ is emphasized.


Figure 1. Kynurenine dysfunction and the common pathways in chronic neurodegenerative disorders (Zadori et al., 2009).

1.1. SCHIZOPHRENIA

SZ is amongst the most common of the severe mental illnesses and one of the top ten causes of global disease burden in adults. It is a chronic psychotic disorder with a lifetime prevalence of about 0.7%, primarily affecting adults, and having a peak age of onset in the early twenties in men, and three or four years later in women. Based on converging evidence from a number of research disciplines, it has been generally accepted that both genetic and environmental factors play a significant role in the etiopathogenesis of SZ. However, the exact nature of these two main etiological factors, their pattern of interaction, and their pathogenic mechanisms are poorly understood, despite extensive neurobiological, clinical, genetic, and epidemiological research.

SZ is formally characterized by three distinct categories of symptoms:

- positive symptoms or psychotic symptoms refer to hallucinations and delusions, abnormality in the form of thoughts and also atypical psychomotor activity;
- negative symptoms like asociality, lack of motivation and abnormality in social interaction;
- cognitive symptoms, including disturbances in selective attention, working memory and executive functions.

Even though the positive symptoms are usually the presenting and the most noticeable clinical features of SZ, cognitive deficits are now recognized as a core domain of the disease for a number of reasons (Green, 1996; Gold, 2004; Keefe, 2007). First, it is well demonstrated that cognitive deficits are relatively stable over time and are also independent from psychotic symptoms. Importantly, cognitive dysfunctions have been found throughout the lifetime of the SZ individuals. Furthermore, it has been shown that patient unaffected relatives have similar cognitive deficits, even if milder. Finally, the severity of these deficits is more predictive than the positive symptoms (Green, 1996).

1.1.1. Cognitive deficits in schizophrenia and alterations in the prefrontal cortex

It is well established that SZ-related cognitive deficits primarily affect central functions that depend, at least in part, on the integrity of the PFC such as working memory, attention and cognitive flexibility (Floresco et al., 2009; Goto et al., 2010; Volk and Lewis, 2010).

The following part of this paragraph focuses on the main components of PFC neuronal circuitry and their possible roles in the SZ cognitive dysfunctions.

- Pyramidal neurons: constitute about 75% of neurons in the cortex. They provide an axon projecting to other brain regions and utilize the excitatory neurotransmitter glutamate acting on the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and the N-methyl-D-aspartate receptors (NMDARs) located on their dendritic spines. Several studies have suggested a reduction in the number of excitatory inputs in SZ, even though it has not been yet elucidated the molecular mechanism(s) underlying these structural abnormalities (Krystal et al., 1994).

- Interneurons: represent approximately 25% of cortical neurons and they use the inhibitory neurotransmitter γ-aminobutyric acid (GABA). They project locally by an axon and regulate the activity of the pyramidal neurons. Post-mortem studies on the brains of SZ individuals have revealed a reduced level of mRNA encoding GAD67, the enzyme responsible for the majority of GABA synthesis, in a subset of cortical interneurons (Hashimoto et al., 2008).

1.1.1.1. Impaired cortical interneurons: relevance for cognitive dysfunctions in schizophrenia

In the last few years emerged that GABA and glutamate neurotransmitters are critically involved in the pathophysiology of SZ (Coyle, 2004; Lewis et al., 2005; O'Donnell, 2012). In fact, a proper balance between the two amino acid transmitters is necessary for the appropriate activity of the PFC and, especially, adequate cognitive functions (Lewis and Moghaddam, 2006).

Several preclinical and clinical studies have shown that local cortical GABA interneurons are critical elements in SZ pathophysiology (Coyle, 2004; Homayoun and Moghaddam, 2006). For example, recent evidence indicates that changes in fast-spiking interneurons are observed blocking the NMDARs (Behrens et al., 2007) and it has also been observed that mice yielded with several signs of a disinhibited cortex after knocking out NMDRs from the calcium-binding protein parvalbumin (PV) interneurons (Belforte et al., 2010), usually predominant in the basket and chandelier subclasses of interneurons (Figure 2).

It has also been suggested that chandelier interneurons may be preferentially involved in the pathophysiology of SZ (Lewis, 1998). Several of the chandelier GABA neurons furnish inhibitory synapses very close to the site action potential generation in pyramidal cells. In this way chandelier interneurons are able to strongly control the excitatory output of the pyramidal neurons that play a pivotal role in working memory and cognitive processes which are altered in SZ (Goldman-Rakic, 1995; Lewis and Anderson, 1995). Furthermore, it has been hypothesized that dysfunctions in the axon terminals of the chandelier GABA neurons could lead to the alterations in GABA neurotransmission observed in SZ patients (Lewis, 1998).

Figure 2. Schematic representation of some cortical circuit alterations found in SZ patients and in animal models of this disorder (Marin, 2012).

Finally, recent studies reported an increased expression of $GABA_A$ receptor α2 subunits in SZ patients. It has been suggested that the pre- and postsynaptic receptor changes are compensatory responses to deficient GABA release from chandelier neurons (Lewis et al., 2005; Gonzalez-Burgos and Lewis, 2008).

1.1.1.2. Deficits in neurons projecting to the prefrontal cortex

It is important to note that inputs from dopaminergic neurons located in the ventral mesencephalon (Figure 3) modulate the activity of both pyramidal and GABA neurons. Thus it is also possible that dysfunctions in dopaminergic signaling contribute to working memory deficits in SZ individuals (Goldman-Rakic et al., 2004). For example it seems that dopaminergic innervation of the PFC is decreased in SZ patients, as indicated by lower levels of expression of tyrosine hydroxylase, the rate limiting enzyme in dopamine synthesis and along with a reduction in the dopamine transporter (Akil et al., 1999). Furthermore, since it has been observed that the inhibition of the dopamine-degrading enzyme catechol-O-methyl transferase (COMT) significantly increases dopamine levels in rats PFC, the availability of extracellular dopamine in the PFC might be reduced in SZ (Tunbridge et al., 2004). It is thought that the hypoactivation that occurs in the PFC may be followed by a compensatory hyperactivation of directly adjacent regions, reproducing a dysfunction in the capacity to engage the functional networks subserving executive functions (Barch, 2005; Glahn et al., 2005; Ragland et al., 2007).

Specifically, numerous studies have revealed marked dysregulations in PFC neurotransmitter systems, involving cholinergic (Mathew et al., 2007; Scarr et al., 2009), glutamatergic (Bauer et al., 2008; Volk and Lewis, 2010), dopaminergic (Guillin et al, 2007) and GABAergic transmission (Volk and Lewis, 2010; Gonzalez-Burgos et al., 2010). In addition, there is a longstanding hypothesis sustaining that the pathophysiology of SZ is associated to dysfunction of selective corticostriatal circuits (Kleist, 1960). Several studies have reported the presence of structural abnormalities in the basal ganglia of SZ individuals (Buchsbaum, 1990) and also neurochemical imbalances in the corticostriatal circuits (Carlsson and Carlsson, 1990).

Figure 3. Schematic illustration of functional deficits in PFC circuitry in SZ (Lewis and Sweet, 2009).

1.2. BASAL GANGLIA

The basal ganglia are a group of subcortical nuclei, where the major input nucleus is represented by the striatum, which is made up of the caudate and putamen. The basal ganglia are traditionally involved in the control of the motor movement, but also in a variety of associative, cognitive and mnemonic functions (Saint-Cyr et al., 1995; Graybiel, 1998; Lalonde and Botez-Marquard, 1997; Yin and Knowlton, 2006; Simpson et al., 2010). The major input to the striatum is derived from the cortex, while the globus pallidus, the subthalamic nucleus and the ventral tegmental area represent the main output nuclei of the basal ganglia. Furthermore, these output structures project to the principal target of the basal ganglia, the thalamus. Finally the thalamus, complete a loop involving the cortex, the striatum and the thalamus itself, projecting back to the cortex (Figure 4) (Alexander et al., 1986).

Figure 4. Simplified picture of the basal ganglia circuitry.

On the basis of the classical view of basal ganglia circuitry, it is reported that the corticostriatal projections are processed within the striatum and then the "transformed signal" is transmitted to the output nuclei of the basal ganglia (Bolam et al., 2000). Thus, basal ganglia are primarily involved in action selection, that is, the decision of which of several possible behaviors to execute at a given time.

9

Dysfunctions in basal ganglia activity play a central role in a number of neurological conditions, including several movement disorders, such as Parkinson's and Huntington's diseases. In fact, these two neurodegenerative pathologies specifically target the basal ganglia. The most important neuropathological alteration in Parkinson's disease is the loss of dopaminergic neurons of the substantia nigra (SN), which causes a severe depletion of striatal dopamine. At variance, the pathological hallmark of Huntington's disease is a massive atrophy of the striatum due to the degeneration of striatal projection neurons, striatal interneurons being relatively spared in the disease.

Studies conducted in humans and non-human primates have demonstrated that the striatum plays a crucial role in more complex forms of behaviours, including decision making and executive function, in addition to modulating motor control and motor learning (Graybiel, 2008). Importantly, it has been shown that lesions performed in the dorsomedial striatum influence spatial working memory in the same way that lesions of the PFC do (Mair et al., 2002; Voorn et al., 2004). Furthermore, the role of the striatum in attentional processes and cognitive control has also been suggested in humans. The measure of the attentional set shifting, in fact, activates the caudate nucleus in healthy human individuals (Rogers et al., 2000). So it has been suggested that working memory and other executive functions are mediated by both the PFC and striatum, working in concert (Simpson et al., 2010).

Particularly, the striatal subregions are involved in the learning processes through at least three distinct circuits:

- a circuit involving associative cortical regions like medial PFC connections to the dorsomedial striatum/caudate;
- sensory and motor cortex circuitry, connected to the dorsolateral striatum/putamen;
- limbic circuitry (*i.e.* limbic cortex, basolateral amygdala and hippocampus) connections to the ventral striatum/nucleus accumbens (Yin and Knowlton, 2006; Yin et al., 2008).

Several studies with brain damaged patients have reported that, by measuring implicit learning using the serial reaction time test, cognitive performance critically

depends on the neostriatum function. In fact patients with damage in the medial temporal lobe were able to learn, while patients with damage in the basal ganglia were cognitively impaired (Knowlton et al., 1994; 1996).

1.2.1. Corticostriatal projections and synaptic targets

It is well known that cortical signals are transmitted within the basal ganglia through the direct and indirect pathways (Albin et al., 1989; DeLong, 1990). Briefly, in the direct pathway cerebral cortical input to the striatum activates the inhibitory projection neurons in the striatum and then the information is transmitted directly to the output nuclei. In the indirect pathway the information coming from the cortex are then transmitted to the output nuclei via the globus pallidus and the subthalamic nucleus (Shink et al., 1996).

The striatum contains a single class of projections neurons, known as medium spiny neurons (MSNs), constituting the 90-95% of the total population of the striatal neurons (Kemp and Powell, 1971), utilizing GABA as their main neurotransmitter. Furthermore, MSNs receive GABAergic synaptic input from striatal cholinergic interneurons, less numerous than MSNs, but able to form extensive connections within the striatum (Tepper et al., 2004).

An equal amount of MSNs belongs to the direct and indirect pathways (Gerfen et al., 2004), in which MSNs express dopamine receptors. It is well known that striatal dopamine released by nigro-striatal neurons, exerts tonic modulation on either MSNs or glutamatergic terminals mainly coming from the motor areas of the cerebral cortex and from the thalamus (Cepeda et al., 1993; Flores Hernandez et al., 1997; Bamford et al., 2004; Centonze et al., 2004; Yin and Lovinger, 2006). The other striatal neurons can be subdivided into three groups: burst-firing GABAergic interneurons, also expressing somatostatin, neuropeptide Y and nitric oxide; GABAergic interneurons expressing PV and cholinergic interneurons (Dani et al., 2007). Several studies have demonstrated that the cortex sends the major inputs to PV-positive GABA interneurons (Lapper et al., 1992; Bennett and Bolam, 1994).

The activation of corticostriatal neurons is followed by the activation of the AMPARs and NMDARs, mainly localized within the synapse (Bernard et al., 1997; Kawaguchi, 1997; Bernard and Bolam, 1998), leading then to the neuronal

depolarization (Wilson, 1993; Kita, 1996). Noteworthy, several studies reported that the PV-positive GABA interneurons receive cortical input and are the principal mediators of inhibition in the striatum, providing a feed-forward inhibition of cortical information to MSNs. Even though the number of PV-positive GABA interneurons is low, they are in a position to strongly control the activity of neurons, giving rise to the output of the striatum, by the direct or indirect pathway (Bolam et al., 2000).

1.3. KYNURENINE PATHWAY AND NEUROACTIVE KYNURENINES

The discovery of the endogenous compound KYNA, more than 150 years ago and the successive understanding of its biosynthesis and chemical structure led to a series of discoveries that turned out to have significant implications for the neurosciences. In fact, it was successively demonstrated that KYNA represented the first of the "kynurenines", a group of metabolically related compounds derived from the essential amino acid tryptophan. Biochemical studies during the first part of the 20th century elaborated the enzymatic steps linking the individual members of the so-called KP, which was found to account for >90% of peripheral tryptophan metabolism in mammals.

The KP started from tryptophan oxidative ring opening and subsequent degradation of the reaction compound. The final product of this metabolic cascade (Figure 5) is the NAD^+ coenzyme, which plays a crucial role in many fundamental biological processes (*i.e.* redox reactions necessary for mitochondrial function).

Figure 5. Tryptophan degradation via KP (Wonodi and Schwarcz, 2010).

This catabolic cascade originates the so-called "kynurenines" deriving directly or indirectly from L-kynurenine (L-KYN), the major primary degradation product of tryptophan. Although the majority of the kynurenines harbor neuroactive properties, the triad of KYNA, quinolinic acid (QUIN) and 3-hydroxy-L-kynurenine (3-HK) is traditionally referred to as 'the neuroactive kynurenines'.

KYNA, one of these metabolites, has long been recognized as a competitive, broad-spectrum antagonist of glutamate receptors. At high, non-physiological, micromolar concentrations, KYNA inhibits NMDARs, kainate receptors and AMPARs (Perkins and Stone, 1982). The action of KYNA on AMPARs has been demonstrated to be dual in a dose-dependent manner, evoking facilitation at lower concentrations, and exerting neuroinhibition at higher concentrations (µM–mM) (Prescott et al., 2006; Rozsa et al., 2008). It has been shown that high concentrations of KYNA display anticonvulsant properties and provide an excellent protection against excitotoxic injury (Foster et al., 1984).

13

It is well known that at much lower (nM) concentrations than those necessary to bind AMPARs, KYNA acts as an antagonist of the glycine allosteric site on the NMDAR and as a non-competitive antagonist of the α7 nicotinic acetylcholine receptor (α7nAChR) (Hilmas et al., 2001), both of which are critically involved in physiological processes underlying learning, memory and other manifestations of synaptic plasticity (Hilmas et al., 2001; MacDonald et al., 2006; Albuquerque et al., 2009).

In the past few years additional targets of KYNA have been identified, such as the former orphan G protein-coupled receptor (Wang et al., 2006) and the aryl hydrocarbon receptor, a nuclear receptor able to recognize aromatic hydrocarbons and 2,3,7,8-tetrachlorodibezo-p-dioxin (DiNatale et al., 2010). Although it has been recently proposed that KYNA is the endogenous ligand for GPR35 (Berlinguer-Palmini et al., 2013), only the α7nAChR as so far been verified as a "bona fide" KYNA receptor in the brain (Hilmas et al., 2001; Grilli et al., 2006; Wu et al., 2010). Other studies have also demonstrated antioxidant properties of KYNA, linked to its ability to scavenge hydroxyl superoxide anion and other free radicals (Lugo-Huiltron et al., 2011).

3-HK, another product of L-KYN degradation and a biological precursor of QUIN is present in the brain at nanomolar concentrations and can generate free radicals and elevate the oxidative stress levels, causing neuronal damage (Okuda et al., 1998). Furthermore, it has also been observed after neuronal exposition to both 3-HK and QUIN a considerable potentiation of excitotoxicity (Guidetti and Schwarcz, 1999). So far no physiological role of 3-HK in the brain has been established and it seems likely that this metabolite does not interact with a specific recognition site (Eastman and Guilarte, 1989).

QUIN possesses excitatory properties due to its capability to directly and selectively stimulate NMDARs, as demonstrated by using selective NMDAR antagonists. In 1978, Lapin observed convulsions after an intracerebroventricular injection of QUIN in mice. This provided the first indication that KP metabolites exert central effects (Stone and Perkins, 1981).

As shown in figure 5, the tryptophan metabolism also includes other metabolites, like 3-hydroxyanthranilic acid (3-HANA) and anthranilic acid; however, until now, direct effects of these metabolites on neuronal activity (Stone, 1993) have not

been demonstrated. Though there are only few examples showing that several kynurenines exhibit pro- and anti-oxidant activities *in vitro* (Giles et al., 2003).

1.3.1. Enzymes involved in the kynurenine pathway

As illustrated in Figure 5, the KP is initiated by the convertion of tryptophan to N-formylkynurenine by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). N-formylkynurenine is then degraded to the pivotal metabolite kynurenine by formamidase. Several studies have reported that the levels of these enzymes in the brain are normally lower than in the peripheral organs. Kynurenine undergoes irreversible transamination to form KYNA by four kynurenine aminotransferases (KATs). So far it has been established that at least two of these enzymes are present in the brain. In the rat brain, KAT I, occurring in a cytosolic and mitochondrial form, could have a major function in cortical maturation. This enzyme is, in fact, selectively expressed in neurons in the perinatal period (Csillik et al., 2002). In the mouse, instead, KAT II is the major enzyme that catalyzes KYNA formation (Yu et al., 2004). Nowadays KAT II is thought to be the main biosynthetic enzyme of KYNA in the mammalian brain (Guidetti et al., 2007). A potent and selective inhibitor of KAT II, (S)-4-ethylsul-fonylbenzoylalanine (ESBA; Pellicciari et al., 2006; Figure 6), has been synthetized.


Figure 6. (S)-4-ethylsul-fonylbenzoylalanine hydrochloride.

Biological assays conducted *in vitro* showed that ESBA inhibits KAT II obtained from partially purified rat liver with an IC_{50} value of 6.1 mM. *In vivo* studies support

these results, demonstrating that the administration of ESBA lowers the extracellular levels of KYNA in the rat striatum (Amori et al., 2009).

A second branch of the KP is characterized by the kynurenine 3-monoxygenase (KMO) and kynureninase, responsible for the synthesis of 3-HK and anthranilic acid, respectively (Chiarugi et al., 1995). Anthranilic acid is then converted to α-amino-ω-carboxymuconic acid semialdehyde that under physiologically conditions spontaneously rearranges to form QUIN. Finally, QUIN is metabolized to nicotinic acid mononucleotide subsequently degraded to the end product NAD^+ (Braidy et al., 2011).

1.3.2. Targets of kynurenic acid

As previously reported, it is generally assumed that KYNA modifies neuronal function because it antagonizes the glycine site of the NMDARs and/or the neuronal α7nAChRs. However, whether the basal levels of KYNA found in brain extracellular spaces are sufficient to interact with these targets is not fully cleared, especially for NMDARs. Another reported target for KYNA is GPR35, an orphan receptor negatively coupled to Gi proteins. GPR35 is expressed both in neurons and other cells (including glia, macrophages and monocytes). KYNA affinity for GPR35 in native systems has not been clarified but current data in modified expression systems suggest that it is quite low. However, it has been proposed that by interacting with GPR35, KYNA may decrease glutamate release in brain and pro-inflammatory cytokines release in cell lines. The inhibition of inflammatory mediator release from both glia and macrophages may explain why KYNA has analgesic effects in inflammatory models (Moroni et al., 2012). Finally, KYNA has been reported as an agonist of aryl hydrocarbon receptor, a nuclear protein involved in the regulation of gene transcription and able to cause immunosuppression after binding with dioxin. Thus, KYNA has receptors in the nervous and the immune systems and may play interesting regulatory roles in cell function. However the roles of GPR35 and aryl hydrocarbon receptor in mediating endogenous KYNA effects remain to be elaborated. Thus, in the following paragraphs the general aspects of α7nAChRs and NMDARs as KYNA molecular targets will be briefly described.

1.3.2.1. Nicotinic receptor

Nicotinic acetylcholine receptors (nAChRs) belong to the superfamily of ligand-gated ion channels and on the basis of their subtypes along with their dendritic, somal, axonal, presynaptic and postsynaptic localization, play a different role in the central nervous system (CNS). For example, it is well established that presynaptically and preterminally located nAChRs increase neurotransmitter release, while postsynaptic and non-synaptic nAChRs generally mediate excitation (Dani and Bertrand, 2007).

nAChRs are constituted from five transmembrane subunits, arranged symmetrically around a central pore. Each subunit comprises four transmembrane domains with both the N- and C-terminus located extracellularly; there are two acetylcholine (ACh) binding sites per receptor (Figure 7).

Figure 7. A schematic representation of the nAChR structure (Karling, 2002).

The structural features of the ligand binding site and the specific amino acid interactions establish the pharmacological properties of a specific nAChR subtype along with the specific amino acid interactions determining conformational transitions (Jensen et al., 2005).

In addition, there are certain ligands that modulate conformational transitions and functions by binding to the subunits or to the interfaces between subunits at positions different from the agonist binding site, leading to the phenomena called

17

as allosteric modulation. It is well known that positive modulators potentiate nAChRs function, while negative modulators inhibit nAChRs function. Notably, the α7nAChRs, one of the well described KYNA target, are good candidate for allosteric modulators because of their unique structural organization, low sensitivity to acetylcholine and fast kinetics. Among the positive allosteric modulators, it is well known that galantamine, physostigmine and codeine, effectively increase α7nAChRs activation at subsaturating agonist concentrations (Pereira et al., 2002).

The most studied nicotinic role in CNS regards the modulation of neurotransmitter release by presynaptic nAChRs. It is well demonstrated that the activation of nAChRs is generally followed by an increase of the release of several neurotrasmitters (McGehee and Role, 1995; Albuquerque et al., 1997; Jones et al., 1999; Sher et al., 2004). For example, exogenous application of nicotinic agonists cause an augmentation in the release of glutamate, GABA and acetylcholine, as well as dopamine and serotonin, while nicotinic antagonists often diminish the release of these neurotransmitters. Particular functional studies revealed that in the rat hippocampus the α7 subunit is at nearly every synapse in the CA1 stratum radiatum (Fabian-Fine et al., 2001); in addition, this subunit was also found on both glutamatergic and GABAergic presynaptic terminals.

The nicotine-induced increase of neurotransmitter release is a consequence of the presynaptic nAChRs activation that initiates a direct and indirect intracellular calcium signal (McGehee and Role, 1995; Wonnacott et al., 1997). Thus, the activity of the presynaptic nAChRs increases intraterminal calcium and contributes to the increased neurotransmitter release. In addition, nicotinic stimulation, increasing glutamate release, promotes synaptic plasticity (Wonnacott et al., 1997; Ge and Dani, 2005).

It has been found that nicotinic receptors are also distributed to preterminal, axonal, dendritic and somatic locations (Lena et al., 1993; Zarei et al., 1999).

1.3.2.2. Influences of nAChRs on cortical functions: relevance for cognition

Wide areas of the brain are innervated by diffuse cholinergic afferents. Cholinergic innervation to the cortex originates from neurons located within basal forebrain nuclei (Wolf, 1991). In addition, a high number of small varicosities that contain

synaptic vesicles does not make synaptic contacts with adjacent neurons, thus producing volume transmission where acetylcholine and choline reach locations distant from the release site (Descarries et al., 1997; Vizi, 2000).

On the basis of their localizations, nAChRs are supposed to modulate cortical activity in a multiple way. For example, it has been observed that activation of nAChRs on distal apical dendrites causes a depolarization of the cell and promotes action potential firing. On the other hand, if the activation occurs in the proximal dendrites nearer to the cell soma, it causes a reduction of the membrane impedance and a shunt of the signals incoming from the apical tuft (Dani et al., 2007).

It is well known that nAChRs are implicated in a wide range of neuronal diseases and mental illnesses (Lena and Changeaux, 1998; Picciotto and Zoli, 2002; Dani and Harris, 2005). Several studies have reported that in Alzheimer's disease, Parkinson's disease and Down syndrome nAChRs are reduced or nicotinic mechanisms are impaired, thus contributing to cognitive dysfunctions (Picciotto and Zoli, 2002; Perry et al., 2000). Notably, it has to take into account that the variable age-related decline of cholinergic transmission and decrease in nAChRs numbers influenced the results.

It has been observed that, generally, nicotinic agonists improve certain forms of memory and nicotinic antagonists and/or cholinergic lesions impair memory. It has been reported in animal studies that acute or chronic nicotine administration, ameliorates working memory. In addition, studies performed in humans using nicotinic agonists have demonstrated an improvement in learning and memory (Levin et al., 2006). Importantly, the responses to nicotinic agonists are highly dose-dependent and those compounds do not have effects at the lowest concentration tested (Dani et al., 2007).

1.3.2.3. nAChRs and schizophrenia

Preclinical and clinical studies provided evidence linking SZ to a deficiency of α7nAChRs-mediated neurotransmission (Deutsch et al., 2005; Martin and Freedman, 2007; Jones et al., 2011). It has been observed that SZ individuals and their biological relatives show a deficient gating of P50 auditory event-related potential and the locus on chromosome 15, which codes the gene for the

α7nAChRs subunit (*i.e.* CHRNA7) (Freedman et al., 1997). Specifically, P50 gating alludes to a paradigm in which two acoustic clicks are given about 500 msec apart, resulting in a reduced P50 response to the second stimulus (Green, 2006).

Furthermore, post-mortem studies examining the brains of SZ individuals have also reported a reduction of the α7nAChR protein levels in the dentate gyrus and CA3 region of the hippocampus along with a degree of global cognitive deficits in these individuals (Martin-Ruiz et al., 2003). In addition, recent studies have also identified significant connections between brain areas of α7nAChRs expression, their impact on other neurotransmitters and how these changes might be linked to the dopamine and glutamate theory of SZ.

Several findings have reported that α7nAChRs are found on midbrain dopamine cells bodies of the ventral tegmental area, subthalamic nuclei, presynaptically on dopamine terminal regions in the striatum, nucleus accumbens and PFC. Moreover α7nAChRs are located on glutamate and GABA neurons that project into dopaminergic regions and terminals (Quik et al., 2000; Dani and Bertrand, 2007; Machaalani et al., 2010). Additionally, dopamine release can be enhanced in several brain regions such as the striatum, ventral tegmental area, nucleus accumbens and PFC, as a result of the α7nAChR activation (Sydserff et al., 2009; Thomsen et al., 2010; Castner et al., 2011). Other studies also reported that α7nAChR activation releases GABA from GABAergic interneurons (Albuquerque et al., 1998; Frazier et al., 1998) and then GABA, acting on $GABA_B$ receptors, leads to a reduction of striatal glutamate release that may, in turn, results in the increased dopamine release (Bencherif et al., 2012). Moreover, it has recently been reported that α7nAChRs modulate glutamate release in the PFC of rats. Notably, kynurenine (the precursor of KYNA) and α-bungarotoxin are able to block choline-induced stimulation of glutamate release (Kondardsson-Geuken et al., 2010).

It has been recognized that interactions between α7nAChRs and NMDARs have been implicated in cognitive deficits observed in SZ (Timofeeva and Levin, 2011). In a recent paper it has also been hypothesized that interactions between α7nAChRs and NMDARs modulate cortical glutamatergic development. In addition, an altered α7nAChR-mediated control of synaptic NMDARs, due to the

loss of the α7nAChRs, may produce permanent changes contributing to cortical impairment present in SZ patients (Lin et al., 2014).

1.3.2.4. N-methyl-D-aspartate receptor

Several studies have shown that hypofunction of the NMDARs has implications in the pathophysiology of SZ. NMDARs are heteromeric protein complexes constituted of at least one NR1 along with several combinations of the NR2 and/or NR3 subunits (Cull-Candy et al., 2001).

Regarding the activation of the NMDARs, it is well known that magnesium blocks the pore of the NMDAR channel, at resting membrane potential. Moreover the NMDAR includes a glutamate recognition site on the NR2 subunit and a glycine or D-serine modulatory site on the NR1 subunit (Johnson and Ascher, 1987; Clements and Westbrook, 1991). In order to activate the NMDAR, it is fundamental that the D-serine/glycine site has to be occupied by glutamate (Figure 8) (Clements and Westbrook, 1991). KYNA acts as an antagonist of the glycine allosteric site on the NMDAR.

Figure 8. Schematic representation of the NMDAR.

Notably, NMDAR has the property of being both voltage-dependent and ligand-gated, giving thus the ability to NMDAR to act as a coincidence detector for presynaptic activity and post-synaptic activity. When the NMDAR is activated, the calcium influx is permitted through the channel, stimulating intracellular signaling cascades that can then influence synaptic plasticity, like long-term potentiation (LTP), underlying several types of learning and memory formation (Nicoll, 2003).

1.3.2.5. Kynurenic acid, α7nAChRs and NMDARs

Since endogenous KYNA is able to inhibit both the NMDARs and the *α*7nAChRs, it is reasonable to hypothesize that it might also be involved in cognitive functions. In addition, as described above, both of these receptors are known to be critical for physiological processes involving synaptic plasticity and more specifically memory and learning (MacDonald et al., 2006; Albuquerque et al., 2009). Thus, fluctuations in KYNA levels could influence these and related phenomena. Several studies reported that increases in brain KYNA levels, induced by the administration of kynurenine, lead to cognitive impairments in experimental animals, thus supporting this concept (*see below*). For example, increased KYNA levels disrupt prepulse inhibition and auditory sensory gating (Shepard et al., 2003; Erhardt et al., 2004) and also cause deficits in contextual learning and memory (Chess and Bucci, 2006; Chess et al, 2007). Thus, dysfunction of α7nAChRs and NMDARs in SZ may be induced or exacerbated by disruptions in the KP. These deleterious effects of KYNA are therefore very interesting in view of the fact that SZ patients present increased KYNA levels in brain and cerebrospinal fluid (CSF) (Erhardt et al., 2001; Schwarcz et al., 2001; Miller et al., 2006; Sathyasaikumar et al., 2011).

1.3.3. Kynurenic acid metabolism and regulation in the brain

In order to provide additional information about the cellular localization of KYNA and QUIN in cerebral tissues, several immunocytochemical and lesion studies have been performed. The results clearly indicate that glial cells, rather than neurons, harbor the enzymatic machinery for the biosynthesis of brain kynurenines. Furthermore, all enzymes involved in the KP are primary contained in astrocytes and microglial cells (Guidetti et al., 1995; Heyes et al., 1996; Schwarcz et al., 1996; Guillemin et al., 2001). In the mammalian brain, the metabolites of the KP are normally present in the nanomolar to micromolar concentration range (Turski et al., 1988; Baran and Schwarcz, 1990; Smythe et al., 2003). The cerebral KP is mainly driven by the pivotal metabolite blood-born kynurenine, which readily enters the brain from the circulation (Figure 9) using the large neutral amino acid transporter (Fukui et al., 1991). Once in the brain, kynurenine is taken up by astrocytes and presumably microglial cells (Speciale and Schwarcz, 1990).

Notably, KYNA synthesis occurs in the astrocytes, as they do not appear to contain kynureninase. Newly produced KYNA is then rapidly released into the extracellular milieu where it has access to neuronal α7nAChRs and NMDARs. On the contrary, very poor KAT activity is present in the microglial cells and, therefore, the QUIN branch of the pathway is favored in these elements (Guillemin et al., 2001).

Because of their polar nature and as so far there are no evidence of efficacious transport processes, KYNA and QUIN very poorly cross the blood-brain barrier (Fukui et al., 1991) and, thus, they must be locally formed within the brain to exert their central effects (Schwarcz et al., 2012).

The intracellular kynurenine concentration determines the enzymatic KYNA formation. Furthermore, the release of KNYA is also influenced by several factors. For example, it has been demonstrated that KYNA formation, in the presence of depolarizing stimuli such as high extracellular K^+ concentration, glutamate receptor agonists or altered cellular energy metabolism, is reduced and hence extracellular KYNA levels. It is noteworthy that in neuron-depleted brain tissue these effects are not observed, suggesting that the glial KYNA synthesis in the brain is controlled by neuronal activity (Gramsbergen et al., 1997). Some studies have also demonstrated that the systemic administration of dopaminergic (Rassoulpour et al., 1998) or cholinergic (Hilmas et al., 2001) agents induced extracellular

fluctuations in KYNA levels in the brain, but not in the periphery. It has also been observed that several of these effects are lost in absence of neurons. Thus KYNA production in, and release from, astrocytes depend on neuronal signals (Gramsbergen et al., 1997).

Figure 9. Dynamics of the cerebral kynurenine pathway in the brain (Schwarcz et al., 2012).

1.3.4. Kynurenic acid and neurotransmission

As shortly mentioned in the previous paragraphs, it appears that SZ is a heterogeneous disease, also characterized by various neurotransmitter imbalances. Namely, corticostriatal neuron loops greatly involved in cognitive skills are functionally impaired. Thus, it becomes relevant that the reported disruption of the KP of tryptophan degradation, in particular the alterations in KYNA levels may cause an exacerbation of the neurotransmitter specific dysregulations observed in SZ (Erhardt et al., 2001; Schwarcz et al., 2001 Miller et al., 2006; Wonodi et al., 2011). For example, it has been demonstrated that extracellular dopamine levels in rat striatum are decreased after intrastriatal infusion of nanomolar concentrations of KYNA. This effect is mediated by α7nAChRs located on the glutamatergic nerve terminals, rather than the NMDARs, since the local perfusion

of KYNA in combination with choline, the selective α7nAChRs agonist, resulted in a prevention of the decrease in extracellular levels of dopamine induced by KYNA (Rassoulpour et al., 2005). In addition, the same study revealed that after treatment with a non-specific astrocyte poisoning leading to an interference with KYNA synthesis, extracellular dopamine levels in the striatum were increased. Thus, dopaminergic tone is regulated by the fluctuations in the astrocytic production of KYNA. Similarly, KYNA induce a reduction in striatal glutamate, first targeting α7nAChRs on glutamatergic nerve terminals. In addition, these results are in line with other studies showing that low concentrations of galantamine, a positive allosteric modulator of α7nAChRs (Santos et al., 2002; Samochocki et al., 2003), prevent the KYNA-induced reduction of extracellular dopamine levels, in the same way of the choline, the direct α7nAChRs agonist (Rassoulpour et al., 2005).

As cognitive deficits affecting SZ individuals involve several central areas, the effects of KYNA have also been evaluated in other brain regions such as PFC and hippocampus. It has been shown that KYNA at nanomolar concentrations induced a reduction in the extracellular glutamate levels, not only in the striatum, but also in the rat PFC (Carpenedo et al., 2001; Rassoulpour et al., 2005; Grilli et al., 2006; Wu et al., 2007, 2008). On the other hand, reductions in the endogenous KYNA synthesis induced an increase in the extracellular levels of glutamate (Wu et al., 2006; 2008) suggesting that KYNA bi-directionally modulate glutamatergic transmission by endogenously formed KYNA. In addition, other studies reported that endogenous KYNA is also able to modulate basal levels of PFC acetylcholine in the rat cortex. Notably, the perfusion of ESBA (Pellicciari et al., 2006), the selective inhibitor of the astrocyte enzyme KAT II which catalyses the KYNA formation from its bioprecursor L-KYN, reduced cortical KYNA levels and increased cortical acetylcholine levels (Zmarowski et al., 2009). Furthermore, the functional effects of nanomolar KYNA concentrations can be replicated by specific α7nAChR ligands (*i.e.* methylcaconitine, α-bungarotoxin) (Rassoulpour et al., 2005; Lopes et al., 2007). On the contrary, these effects are not observed using selective antagonist of the glycine$_B$ site of the NMDARs (Hilmas et al., 2001).

1.3.5. Possible relevance of astrocyte-derived kynurenic acid

Since astrocytes are responsible for the *de novo* synthesis of KYNA from L-kynurenine in the brain, these cells deserve consideration as modulators of α7nAChRs function and consequently also cholinergic transmission (Zmarowski et al., 2009).

For much of the past century, astrocytes were considered just as a subtype of glial cell that contacts synapses and the vasculature, providing metabolic support to the neurons. Recent experimental evidence suggests that in addition to being essential supporters of neuronal function, astrocytes also closely interact with neurons and participate in the regulation of synaptic neurotransmission. It has been proposed that synapses are tripartite, where the astrocytic process is associated with the presynaptic and postsynaptic elements of the synapses. In addition, it has also been demonstrated that astrocytes possess a large array of neurotransmitter receptors (Araque et al., 1999; Halassa et al., 2007) and they can also release chemical transmitters such as, among others, glutamate, GABA and glycine. In addition, impairments of the bi-directional communication between astrocytes and neurons, lead to an abnormal neurotransmission and information processing. Thus, it has been hypothesized that the astrocytes could also be involved in various manifestations of brain dysfunctions (Kettenmann and Ransom, 2004; Tian et al., 2005). Importantly, astrocytes may also regulate synaptic communication through volume transmission, the diffusion through the brain extracellular fluid of neurotransmitters released at points that may be remote from the target cells with the resulting activation of extrasynaptic receptors (Agnati and Fuxe, 2000).

Biochemical and immunocytochemical studies, demonstrated that astrocytes are the major source of KYNA in the mammalian brain (Ceresoli-Borroni, et al., 1999; Rejdak et al., 2003; Melendez-Ferro et al., 2005). Thus, in the brain, changes in extracellular KYNA concentrations reflect similar fluctuations in intracellular KYNA formation, determined by intra-astrocytic control mechanisms (Schwarcz and Pellicciari, 2002). These regulatory events are likely to influence the neuromodulatory effects of astrocyte-derived KYNA in the normal and diseased human brain. For example, it has been reported that fluctuations in the astrocytic production of KYNA, through indirect local actions possibly involving volume transmission, inversely regulate striatal dopaminergic tone. Such a mechanism

may profoundly influence dopamine function under physiological and pathological conditions (Wu et al., 2007). From a pathological point of view, it has been proposed (*see above*) that astrocytes lack kynurenine-hydroxylase so that large amounts of kynurenine KYNA are produced, while minor amounts of QUIN are normally synthesised. This suggests that astrocytes alone are neuroprotective by minimising QUIN production and maximising synthesis of KYNA. However, kynurenine added to macrophages led to significant production of QUIN. Thus, in the presence of macrophages and/or microglia, astrocytes could be neurotoxic by producing large concentrations of kynurenine that can be metabolised by neighbouring monocytic cells to QUIN (Guillemin et al., 2001).

1.3.6. Kynurenine pathway and brain dysfunctions

Kynurenines have become recognized as key players in the mechanism leading to neuronal damage, neurodegenerative pathologies and neuroimmunological disorders (Table 1). As already reported, a link between endogenous kynurenines and excitotoxic phenomena has been suggested (Vecsei et al., 2012). In addition, it is now generally accepted that a dysfunction of the KP metabolism may have untoward effects on brain functions (Schwarcz et al., 2012). However, the exact nature of the cellular and molecular events underlying these effects is not yet definitively established. Among other hypotheses, it has been proposed that some pathologies of the CNS could be due to an imbalance of KYNA, QUIN and 3-HK alone or in concert (Schwarcz and Pellicciari, 2002; Schwarcz et al., 2012; Szalardy et al., 2012; Vecsei et al., 2012). Furthermore, several experimental animal studies have also investigated the possible secondary role of the KP, as mediator of central dysfunctional states. Thus, it has been demonstrated that in presence of pathogenic events, kynurenine brain levels are often abnormal (Stone, 2002).

Metabolite	↑/↓	Molecular Event	Pathology (Cellular/Clinical)
3-HK	↑	Free radical generation	Apoptosis, potentiation of excitotoxicity, cataract formation, neurodegenerative diseases, stroke, traumatic injury, neurovirological diseases, neuroinflammation
QUIN	↑	NMDA receptor activation, free radical generation	Excitotoxicity, neurodegenerative diseases, stroke, traumatic injury, epilepsy, cerebral malaria, perinatal hypoxia, neurovirological diseases, neuroinflammation
KYNA	↑	NMDA receptor blockade, α7 nicotinic acetylcholine receptor blockade	Cognitive impairment, schizophrenia
	↓		Neurodegenerative diseases, pain, drug abuse

Table 1. Correlation between neuroactive kynurenines and central nervous system pathologies (Schwarcz and Pellicciari, 2002).

For example, it has been observed that substantial elevations of 3-HK and QUIN levels occur in response to the activation of glial cells or when macrophages infiltrate the brain during immunological compromises. Since the KAT activity is very low in microglia, the increases in 3-HK and QUIN come with relatively modest changes in KYNA formation. Furthermore, has not so far been consistently seen a reduction in the brain levels of neuroactive kynurenines after injurious events. This could be explained by the fact that if localized neuroactive kynurenine level reductions take place, they are probably obscured by the upregulation of kynurenine synthesis in reactive glial cells (Schwarcz and Pellicciari, 2001).

It is noteworthy that the fundamental basis of the KP metabolism characterized in rodents and other mammals might be also applied to humans. Numerous post-mortem studies have investigated about the disposition of kynurenines in the human brain along with analysis in serum and CSF. These studies revealed that almost always diseases affecting the human brain shown KP-related changes that parallel those seen in relevant animal models (Stone, 2001).

However, not all disease-linked changes in cerebral kynurenine metabolism in humans can be easily associated to animal studies. For example, so far, it is not clear why in the end-stage of Huntington's disease KYNA levels are markedly reduced (Beal et al., 1990) or why in SZ KYNA levels are elevated in the cortex (Schwarcz et al., 2001).

1.3.7. Kynurenic acid and schizophrenia

Clinical studies have reported that KYNA concentrations were significantly increased in PFC and CSF of SZ patients (Erhardt et al., 2001; Schwarcz et al., 2001). Furthermore, it has also been demonstrated that the upregulation of KYNA levels in SZ was associated with elevations in the tissue levels of L-kynurenine, the KYNA's immediate bioprecursor (Figure 8) (Schwarcz et al., 2001).

It was originally thought that the high levels of L-kynurenine seen in SZ patients could be a direct consequence of its increased synthesis catalyzed by either TDO or IDO, based on the evidence that both of them are dysregulated in inflammatory and immune sensitization events. However, recent studies have demonstrated that even though the expression of TDO gene is significantly increased in SZ patients, these dysregulations seem to be exacerbated in individuals with additional risk genes. Furthermore, brain IDO gene expression seems to be normal in individuals affected by SZ. Thus, more recently a different mechanism possibly involved in the observed increased KYNA levels in SZ patients has been proposed. In particular, it has been suggested that a reduction in KMO activity in the periphery and/or in the brain of SZ subjects could lead to abnormally high cortical concentrations of L-kynurenine and, subsequently, to high KYNA levels. In fact, KMO, the enzyme converting L-kynurenine to 3-HK, shows much higher activity in peripheral tissues than in the brain. Thus, it seems likely that under certain physiological conditions or during pathological events, an increase of L-kynurenine levels might overstep the catabolic capacity of KMO, thus leading to brain KYNA formation (Figure 10; Wonodi and Schwarcz, 2010).

Figure 10. Kynurenine pathway in schizophrenia (Wonodi and Schwarcz, 2010).

The high concentrations of brain KYNA levels in the PFC of SZ individuals, may be clinically relevant since it is well established that hypofunction of both NMDAR and the α7nAChR are implicated in SZ pathophysiology and, in particular, in the cognitive deficits associated with the disease.

2. AIM

Dysregulations of the KP pathway of tryptophan degradation, causing hyper- or hypofunction of active metabolites, have been associated with several CNS disorders, as widely described in the Introduction. In particular KYNA, a neuroactive metabolite of the KP, has received in the last decades considerable attention from neurobiologists and neuroscientists. The reasons of this interest derive from the observations that even relatively low fluctuations in brain KYNA levels have pronounced consequences, influencing neurotransmission and affecting cognitive and motor behaviors in experimental animals (Schwarcz et al., 2012). Consciousness of these bi-directional effects has led to the hypothesis that endogenous KYNA is a significant neuromodulator in the mammalian brain. Notably, this role likely extends to pathological situations, which frequently present with significant changes in brain KYNA levels. Examples include catastrophic neurodegenerative disorders (e.g. Huntington's disease and Alzheimer's disease) as well as psychiatric diseases (e.g. SZ) (Schwarcz et al., 2012; Szalardy et al., 2012). Therefore, understanding the nature and characteristics of the remarkable neuromodulatory properties of KYNA have implications for brain physiology and pathology alike.

Previous studies demonstrated that increased KYNA concentrations reduce extracellular dopamine and glutamate levels in distinct brain regions such as the striatum, the PFC and the hippocampus (Carpenedo et al., 2001; Rassoulpour et al., 2005; Grilli et al., 2006; Wu et al., 2010; Banerjee et al., 2012) and these effects have been associated to KYNA-induced neuroprotection or CNS dysfunctions. On the contrary, no studies previously investigated the possibility that endogenous KYNA might also influence the *in vivo* levels of GABA, the major inhibitory neurotransmitter in the mammalian brain. As such an effect may have significant physiological consequences and may also have implications for pathological events, in the present study we acutely manipulated KYNA levels and assessed extracellular GABA concentrations over time through microdialysis studies in the striatum and the PFC of awake, freely moving rats. These two brain regions were chosen because they play essential roles in cognitive processes and

the striatum is also involved in various neuropathological disturbances, such as Huntington's and Parkinson's diseases in which dysfunctions in KP have been largely documented. Finally, as a previous electrophysiology study demonstrated that α7nAChR-dependent glutamatergic transmission is more sensitive to KYNA than α7nAChR-dependent-GABAergic signaling in hippocampal cell cultures (Banerjee et al., 2012; Albuquerque and Schwarcz, 2013), the present research included parallel determinations of extracellular GABA and glutamate levels both in the rat striatum and PFC.

3. MATERIAL AND METHODS

3.1. MICRODIALYSIS

Cerebral microdialysis is a well-established laboratory tool which permits the monitoring of neurotransmitters and other biological molecules from interstitial fluids. This method is widely used for sampling and quantifying neurotransmitters, neuropeptides, and hormones in the brain and periphery. Depending on the availability of an appropriate analytical assay, virtually any soluble molecule in the interstitial space fluid can be measured by microdialysis. In addition, microdialysis is being increasingly used as a bedside monitor to provide on-line analysis of brain tissue biochemistry during neurointensive care.

The microdialysis concept is based on the biological tissue implantation of a catheter consisting of a fine double lumen probe, lined at its tip with a semi-permeable dialysis membrane. The probe is then perfused via an inlet tube with fluid isotonic to the tissue interstitium. The perfusate passes along the membrane before exiting via outlet tubing into a collecting chamber (Figure 11). Diffusion drives the passage of molecules across the membrane along their concentration gradient. Molecules at high concentration in the brain extracellular fluid pass into the perfusate with minimum passage of water and, as the perfusate flows and is removed at a constant rate, the concentration gradient is maintained. It is usually state that the microdialysis probe therefore acts an artificial blood capillary and the concentration of substrate in the collected fluid (microdialysate) will depend in part on the balance between substrate delivery to, and uptake/excretion from, the extracellular fluid (Figure 11). This simple concept provides a powerful technique with many potential applications in which any molecule small enough to pass across the membrane can be sampled.

Microdialysis is also commonly used for the continuous and local administration of exogenous compounds (reverse microdialysis). In this case, the compound of interest is dissolved into the perfusion medium.

Figure 11. Schematic picture illustrating the principle of microdialysis sampling.

As previously reported, microdialysis probes are constituted of a length of tubular dialysis membrane through which a solution is constantly perfused. The dialysis membrane is semipermeable and permits free transport of some but not all solutes. Permeability is typically limited to compounds with molecular masses <20,000 Da. A variety of membranes are available which differ in pore size and material used. The length of the membrane is chosen based on the dimension of the brain area under examination. In this study we used 2 mm membrane length probes.

It has been clearly demonstrated that the concentration of a given molecule in the dialysate will be lower than its real concentration in the brain extracellular fluid unless there is total equilibration across the dialysis membrane. The proportion of

the true concentration collected in the dialysate is termed the relative recovery and is dependent on membrane pore size, membrane area, rate of flow of perfusate and diffusion speed of the substance.

In *vivo* microdialysis is not without limitations. While suitable for the real-time measurement of endogenous substances, animal studies have shown that prolonged probe placement results in edema in the surrounding region and infiltration of the membrane by inflammatory cells, rendering the results obtained in such a situation unreliable. This problem has been surmounted in the closed technique in which the modification of the probe is such that it is inserted into a relatively superficial "bolt" which may be locked upon removal of the probe. This technique of repeated probe insertion has been employed in animal studies and has not been shown to be associated with any increase in gliosis in the region of probe placement. Thus, the aspect of this technique that ensures minimal trauma to the cerebral parenchyma may be preserved along with the benefit of continuous, serial sampling. Another proposed benefit to the technique of intermittent sampling as opposed to the use of a continuous indwelling probe is the decreased risk of infection.

3.2. ANIMALS

Adult male Sprague-Dawley rats (225-250 g, Harlan Italy S.r.l., Udine, Italy) were used. The animals, housed in cages in groups of five animals in a temperature- and relative humidity- controlled environment with a regular 12 hour light/dark cycle, had free access to food and water. Following delivery, the animals were allowed to adapt to the environment for at least one week before the experiment commenced.

Experiments were carried out in strict accordance with the European Communities Council Directive (86/609/EEC) and the Guidelines released by the Italian Ministry of Health (D.L. 116/92) and (D.L. 111/94-B). A formal approval to conduct the experiments described was obtained by the local Ethics Committee (University of Ferrara, Italy). Efforts were made to minimize the number of animals used and to reduce pain and discomfort. The ARRIVE guidelines for reporting research (http://www.nc3rs.org.uk/ARRIVE) were followed throughout the design and execution stage of all experiments.

3.3. MICRODIALYSIS EXPERIMENTS

3.3.1. Surgery

On the day of surgery, the animals, kept under isoflurane anaesthesia (1.5% mixture of isoflurane and air), were mounted in a David Kopf stereotaxic frame (Tujunga, CA, USA) with the upper incisor bar set at -2.5 mm below the interaural line. After exposing the skull and drilling a burr hole, a guide cannula (CMA12; CMA Microdialysis, Solna, Sweden) was positioned on top of the striatum (stereotaxic coordinates = AP: 1 mm anterior to bregma, L: 2.5 mm from the midline, V: 3.5 mm below the dura) or in the medial PFC (AP: 3.2 mm anterior to bregma, L: 0.6 mm from the midline; V:2.0 mm below the dura; Paxinos & Watson, 1986) and secured to the skull with anchor screws and acrylic dental cement. After surgery, the animals were housed individually in microdialysis chambers.

3.3.2. Experimental protocol

On the day after surgery, a microdialysis probe of concentric design (CMA12; molecular weight cutoff: 20 kD; outer diameter 0.5 mm; length of dialysing membrane 2 mm; Alfatech S.p.A., Genova, Italy) was inserted through the guide cannula, extending throughout the striatum or the PFC. The probe was connected to a microperfusion pump (CMA 100; Carnegie Medicin, Stockholm, Sweden) set to a speed of 1 µl/min and perfused with Ringer solution containing (in mM): NaCl, 144; KCl, 4.8; MgSO4, 1.2; CaCl2, 1.7; pH 6.7 (Figure 12). The probe was employed both for intrastriatal or intracortical perfusion with the selected compounds and the recovery of perfusate samples for measurement of local glutamate and GABA levels. Perfusates were collected every 30 min. After three stable basal glutamate and GABA values were obtained, KYNA (30-1000 nM), galantamine (5 µM), ESBA (1 mM, 5 mM) 7-Cl-KYNA (100 nM) and/or CNQX (100 µM) were locally perfused for 2 h (four samples). Subsequently, perfusion with Ringer solution continued for another 2.5 h (5 samples). In some experiments performed in the striatum, tetrodotoxin (TTX; 2 µM) was locally perfused 3.5 h prior to the addition of KYNA, and perfusion continued until the end of the experiment.

Following each experiment, the brain was removed from the skull, and the position of the dialysis probe was verified using 30 µm-thick coronal cryostat sections. Only those animals in which the probe was correctly located were included in this study.


Figure 12. Schematic representation of the experimental protocol. In 1 is illustrated the microinfusion pump that is connected to a syringe selector as shown in 2, perfusing in the probe represented by 3. In 4 is illustrated a swivel, to permit a free movement of the animal and 5 represent the fractional collector.

3.3.3. Glutamate and GABA analysis

Glutamate and GABA levels in the dialysate were measured by HPLC coupled to fluorimetric detection. Briefly, 25 µl samples were pipetted into glass microvials and placed in a temperature-controlled (4°C) Triathlon autosampler (Spark Holland, Emmen, The Netherlands). Thirty µl of o-phthaldialdehyde/mercaptoethanol reagent were added to each sample, and 30 µl of the mixture were injected onto a Chromsep analytical column (3 mm inner diameter, 10 cm length; Chrompack, Middelburg, The Netherlands). The column was eluted at a flow rate of 0.48 ml/min (Beckman125 pump; Beckman Instruments, Fullerton, CA, USA) with a mobile phase containing 0.1 M sodium acetate, 10% methanol and 2.2% tetrahydrofuran (pH 6.5). Glutamate and GABA were detected by means of a Jasco fluorescence spectrophotometer FP-2020

Plus (Jasco, Tokyo, Japan). The retention times of glutamate and GABA were ~3.5 and ~ 15.0 min, respectively.

3.4. MATERIALS

KYNA, 7-Cl-KYNA, CNQX, TTX and galantamine were obtained from Sigma Chemical Co. (St. Louis, MO, USA). For administration by reverse microdialysis, KYNA, 7-Cl-KYNA, CNQX, and galantamine were dissolved in Ringer solution and delivered through the probe. TTX was dissolved in water at a concentration of 1 mM and stored at -80°C. Upon thawing, the toxin was diluted in Ringer solution on the day of the experiment. ESBA, kindly provided by R. Pellicciari (University of Perugia, Italy), was synthesized and used in microdialysis experiments as described (Pellicciari et al., 2006). All other chemicals were of the highest commercially available purity.

3.4.1. Data management and statistical analysis

Data were not adjusted for recovery from the microdialysis probe. Results from individual time points are reported as percentages of the mean of the last three baseline samples before treatment commenced. For experiments involving KYNA and TTX, results from individual time points are reported as percentages of the mean of the three samples prior to KYNA perfusion. Data are expressed as the mean ± SEM, and only the statistical significance of the peak effects (maximal responses) is shown in the Figures. In addition, the area created by the curve (AUC), reflecting the duration of the effect, was determined for each animal. Area values (overall effects) were calculated as percentages of changes in baseline value over time by using the trapezoidal rule. Statistical analysis was carried out by analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple comparisons.

4. RESULTS

4.1. STRIATUM

4.1.1. Basal extracellular GABA and glutamate levels

Basal extracellular GABA and glutamate levels, measured in 30 min dialysate fractions, were 19.4 ± 0.8 nM and 327 ± 18 nM (n = 23), respectively.

In control rats, these levels remained essentially stable over the duration of the experiment (6 h), with a fluctuation of no more than 5-6%.

4.1.2. Effects of intrastriatal KYNA perfusion

Local perfusion with KYNA (30-1000 nM) caused concentration-dependent decreases in extracellular GABA levels (Figure 13A). This reduction was already seen in the first sample after the introduction of KYNA, and GABA levels gradually returned to baseline values after KYNA was removed from the perfusion solution. A statistically significant effect was obtained with 100 nM KYNA, and relatively small further reductions were seen after perfusion with higher concentrations of KYNA (Figure 13A; maximal decrease to 57 ± 4 % of control values at 1000 nM KYNA). Statistical assessment of the AUC revealed that the effects of 300 nM and 1000 nM KYNA exceeded the effects of 100 nM KYNA (Figure 13B).

As shown in Figure 14, local perfusion with KYNA also caused a concentration-dependent reduction in extracellular glutamate levels. A statistically significant effect was obtained with 100 nM KYNA, and relatively small further reductions were seen after perfusion with higher concentrations of KYNA (Figure 14; maximal decrease to 57 ± 8 % of control values at 300 nM KYNA). Statistical assessment of the AUC revealed that the effects of 300 nM and 1000 nM KYNA exceeded the effects of 100 nM KYNA (Figure 14B).

Figure 13. Effect of kynurenic acid (KYNA) on extracellular GABA levels in the rat striatum. KYNA was applied for 2 h by reverse microdialysis (bar). See text for absolute levels of extracellular GABA. A: data (means ± SEM; n = 6 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05, **P<0.01 compared to both controls and 30 nM KYNA; °P<0.05 compared to the effects of 100 nM KYNA.

Figure 14 Effect of kynurenic acid (KYNA) on extracellular glutamate levels in the rat striatum. KYNA was applied for 2 h by reverse microdialysis (bar). See text for absolute levels of extracellular glutamate. A: data (means ± SEM; n = 6 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *$P<0.05$, **$P<0.01$ compared to both controls and 30 nM KYNA; °$P<0.05$ compared to the effects of 100 nM KYNA.

4.1.3. Effects of intrastriatal 7-Cl-KYNA perfusion

Intrastriatal perfusion of 7-Cl-KYNA (100 nM), a NMDAR antagonist acting at the glycine$_B$ site, did not affect extracellular GABA and glutamate levels. Moreover, co-perfusion with 7-Cl-KYNA (100 nM) did not influence the reduction in extracellular GABA and glutamate levels caused by 100 nM KYNA (Figure 15 and 16).

Figure 15. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P < 0.01$ compared to both controls and 7-Cl-KYNA alone.

Figure 16. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P < 0.01$ compared to both controls and 7-Cl-KYNA alone.

4.1.4. Effects of intrastriatal galantamine perfusion

Intrastriatal perfusion of galantamine (5 µM) moderately, but significantly, increased local extracellular GABA and glutamate levels. These effects were transient, and the aminoacid concentrations promptly reverted to baseline values following the removal of galantamine from the perfusion solution. When galantamine (5 µM) and KYNA (100 nM) were co-infused, extracellular GABA and glutamate levels remained unchanged compared to the respective baseline values (Figure 17 and Figure 18).

Figure 17. Effects of 5 μM galantamine, perfused alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *$P<0.05$ compared to both controls and galantamine + KYNA.

Figure 18. Effects of 5 µM galantamine, perfused alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05 compared to both controls and galantamine + KYNA.

4.1.5. Effects of intrastriatal ESBA perfusion

Intrastriatal perfusion of ESBA (1 mM), a specific inhibitor of KYNA's biosynthetic enzyme KAT II (Pellicciari et al., 2006), reduces the extracellular concentration of KYNA, reaching a nadir of 68% of baseline values after 1.5 h (Amori et al., 2009). In the present experiments, this treatment increased extracellular GABA levels, reaching a peak value of 156 ± 6% of baseline after 1 h (Figure 19). GABA levels gradually returned to control values after ESBA was removed from the perfusion solution. Co-application of KYNA (100 nM) completely abolished the effect of ESBA (1 mM) on extracellular GABA levels (Figure 19).

Intrastriatal perfusion of ESBA (1 mM) also increased extracellular glutamate levels, and this effect, too, was neutralized by co-perfusion of KYNA (100 nM; Figure 20).

Figure 19. Effect of 1 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P < 0.01$ compared to both controls and (ESBA + KYNA).

Figure 20. Effect of 1 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P<0.01$ compared to both controls and (ESBA + KYNA).

4.1.6. Effects of intrastriatal perfusion with TTX in combination with ESBA

As shown in Figure 21 and 22, when TTX (2 µM) was included into the perfusion medium 2 h before the onset of the collection period till the end of the experiment, it significantly but partially ($p < 0.05$) counteracted the ESBA (1 mM)-induced increase in both extracellular GABA and glutamate levels.

By itself TTX induced a slight reduction in both extracellular GABA and glutamate levels. These effects were significant ($P < 0.05$) by evaluating the areas under the curves, but not the time point effects (Figure 23 and 24).

Figure 21. Effect of tetrodotoxin (TTX) perfusion on (S)-4-(ethylsulfonyl)benzoylalanine (ESBA; 1 mM)-induced increase in extracellular GABA levels in the rat striatum. TTX (2 μM) was included into the perfusion medium 2 h before the onset of the collection period till the end of the experiment (open bar), while ESBA was applied for 2 h by reverse dialysis (black bar). A: data (means SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by Student's t-test. *P<0.05 compared to controls.

Figure 22. Effect of tetrodotoxin (TTX) perfusion on (S)-4-(ethylsulfonyl)benzoylalanine (ESBA; 1 mM)-induced increase in extracellular glutamate levels in the rat striatum. TTX (2 µM) was included into the perfusion medium 2 h before the onset of the collection period till the end of the experiment (open bar), while ESBA was applied for 2 h by reverse dialysis (black bar). A: data (means SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by Student's t-test. Data were analyzed by Student's t-test. *$P < 0.05$ compared to controls.

Figure 23. Effect of tetrodotoxin (TTX) on extracellular GABA levels in the rat striatum. TTX was applied for 4.5 h by reverse microdialysis (bar). See text for absolute levels of extracellular GABA. A: data (means ± SEM; n = 5 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05, compared to controls.

Figure 24. Effect of tetrodotoxin (TTX) on extracellular glutamate levels in the rat striatum. TTX was applied for 4.5 h by reverse microdialysis (bar). See text for absolute levels of extracellular glutamate. A: data (means ± SEM; n = 5 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05, compared to controls.

4.2. PREFRONTAL CORTEX

4.2.1. Basal extracellular GABA and glutamate levels

Basal extracellular GABA and glutamate levels, measured in 30 min dialysate fractions, were 38.7 ± 3.9 nM and 385 ± 33 nM (n = 22), respectively. In control rats, these levels remained essentially stable over the duration of the experiment (6 h), with a fluctuation of no more than 5-7%.

4.2.2. Effects of intra-PFC KYNA perfusion

Local perfusion with KYNA (30-300 nM) caused a concentration-dependent decrease in extracellular GABA levels. This reduction was already seen in the first sample after the introduction of KYNA, and GABA levels gradually returned to baseline values after KYNA was removed from the perfusion solution. A statistically significant effect was obtained with 100 nM KYNA, and further reductions were seen after perfusion with higher concentrations (Figure 25) (maximal decrease to 48 ± 7 % of control values at 300 nM KYNA). Statistical assessment of the AUC revealed that the effects of 300 nM KYNA exceeded the effects of 100 nM KYNA (Figure 25).

Local perfusion with KYNA (30-300 nM) was also associated with concentration-dependent decreases in extracellular glutamate levels (Figure 26). A statistically significant effect was obtained with 100 nM KYNA, and further reductions were seen after perfusion with higher concentrations (Figure 26) (maximal decrease to 69 ± 8 % of control values at 300 nM KYNA). Statistical assessment of the AUC revealed that the effects of 300 nM KYNA exceeded the effects of 100 nM KYNA (Figure 26).

Figure 25. Effect of kynurenic acid (KYNA) on extracellular GABA levels in the rat PFC. KYNA was applied for 2 h by reverse microdialysis (bar). See text for absolute levels of extracellular GABA. A: data (means ± SEM; n = 6 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. $*P<0.05$, $**P<0.01$ compared to both controls and 30 nM KYNA; $°P<0.05$, $°°P<0.01$ compared to the effects of 100 nM KYNA.

Figure 26. Effect of kynurenic acid (KYNA) on extracellular glutamate levels in the rat PFC. KYNA was applied for 2 h by reverse microdialysis (bar). See text for absolute levels of extracellular glutamate. A: data (means ± SEM; n = 6 per group) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of change in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. *$P<0.05$, **$P<0.01$ compared to both controls and 30 nM KYNA; °$P<0.0$ compared to the effects of 100 nM KYNA.

4.2.3. Effects of intra-PFC 7-Cl-KYNA perfusion

As observed in the striatum, intra-PFC perfusion of 7-Cl-KYNA (100 nM) did not affect extracellular GABA and glutamate levels. Moreover, co-perfusion with 7-Cl-KYNA (100 nM) did not influence the reduction in extracellular GABA (Figure 27) or glutamate (Figure 28) levels caused by 100 nM KYNA.

Figure 27. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P < 0.01$ compared to both controls and 7-Cl-KYNA alone.

Figure 28. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P<0.01$ compared to both controls and 7-Cl-KYNA alone.

4.2.4. Effects of intra-PFC galantamine perfusion

Intra-PFC perfusion of galantamine (5 µM) did not induce significant changes in local extracellular GABA and glutamate levels on its own. This profile of action is different from that displayed by the compound in the striatum (*see above*). When galantamine (5 µM) and KYNA (100 nM) were co-infused, extracellular GABA and glutamate levels remained unchanged compared to the respective baseline values (Figure 29 and 30).

Figure 29. Effects of 5 µM galantamine, perfused alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons.

Figure 30. Effects of 5 µM galantamine, perfused alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons.

4.2.5. Effects of intra-PFC ESBA perfusion

Intra-PFC perfusion of ESBA reduces the extracellular concentration of KYNA (Wu et al., 2010). In the present study, perfusion with ESBA (5 mM) increased extracellular GABA levels, which reached a peak value 155 ± 11% of baseline after 1.5 h (Figure 31). GABA levels gradually returned to control values after ESBA was removed from the perfusion solution. Co-application of KYNA (30 nM) completely abolished the effect of ESBA (5 mM) on extracellular GABA levels.

Intracortical perfusion of ESBA (5 mM) also increased extracellular glutamate levels. However, this effect reached a peak value 162 ± 9% of baseline after 0.5 h (Figure 32) and seems to be less prolonged than that observed measuring GABA levels.

The effect of ESBA on extracellular glutamate levels was neutralized by co-perfusion of KYNA (30 nM; Figure 32).

Figure 31. Effect of 5 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused alone or in combination with 30 nM KYNA, on extracellular GABA levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **P<0.01 compared to both controls and (ESBA + KYNA).

Figure 32. Effect of 5 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused alone or in combination with 30 nM KYNA, on extracellular glutamate levels in the rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple comparisons. **$P < 0.01$ compared to both controls and (ESBA + KYNA).

4.2.6. Effects of intra-PFC CNQX perfusion

Perfusion of CNQX (100 µM), an AMPA/kainate receptor antagonist, did not induce significant changes in extracellular GABA or glutamate levels in the PFC (Figure 33 and 34).

Figure 33. Effect of 100 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) on extracellular GABA levels in the rat PFC. CNQX was applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by Student's t-test.

Figure 34. Effect of 100 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) on extracellular glutamate levels in the rat PFC. CNQX was applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the averaged three baseline values prior to treatment. B: bargraphs of the areas under the curves, calculated as the percentage of changes in basal values over time. Data were analyzed by Student's t-test.

5. DISCUSSION

Once upon a time, KYNA was considered one of the numerous inert tryptophan metabolites existing in mammalian urines. Its name, in fact, was coined by Liebeg in the second half of the 19th century and means "acid in dog urines". Subsequently, its molecular structure was clarified and the compound was chemically synthesized at the beginning of the 20th century. This led to a series of discoveries that turned out to have significant implications in neuropharmacology field. It is now clear that KYNA was the first of the so-called "neuroactive kynurenines", a group of metabolically related compounds (*see* Introduction) able to influence brain function. More importantly, it has been demonstrated that KP metabolites, including KYNA, play a relevant role not only in brain physiology but also as potential causative factors in several devastating brain diseases. As a consequence, over the last years there have been intensified efforts to better understand the neuromodulatory activity of KYNA under physiopathological conditions.

In the present research, the *in vivo* effects of KYNA on endogenous extracellular glutamate and GABA levels in the striatum and PFC of the awake rats have been investigated. Taken together, the present results demonstrated that nanomolar (*i.e.* physiological) concentrations of KYNA significantly and concentration-dependently influence extracellular glutamate and GABA levels in the both brain areas of awake, freely moving rats. They also indicate that the selective NMDAR antagonist 7-Cl-KYNA, which is ~20 times more potent than KYNA as an NMDAR antagonist but does not inhibit α7nAChR function (Parsons et al., 1997; Hilmas et al., 2001), does not reduce glutamate and GABA levels on its own and does not modify the KYNA-induced decrease in GABA levels. In addition, co-administration of galantamine, a positive allosteric modulator of the α7nAChRs (Lopes et al., 2007), prevents the KYNA-induced decrease in striatal and PFC glutamate and GABA levels, thus suggesting a possible role of α7nAChRs in the interaction between KYNA and aminoacidergic transmission in the two brain regions. Finally, inhibition of endogenous KYNA production by the KAT II inhibitor ESBA results in an augmentation of extracellular glutamate and GABA levels, which is neutralized by the addition of KYNA. The results from these acute experiments provide

evidence for a bi-directional regulation of extracellular glutamate and GABA levels by endogenous KYNA, and may be relevant for our understanding of physiopathological role of this neuroactive kynurenine in the brain. The effects of KYNA level fluctuations on extracellular glutamate and GABA levels in the rat striatum could have functional consequences which partly differ from those due to the changes in PFC KYNA concentrations. Thus, in the present paragraph the *in vivo* effects of KYNA on endogenous extracellular glutamate and GABA levels in the two brain regions are separately discussed.

5.1 Striatum

The present results firstly confirm that KYNA reduces striatal glutamate levels (Moroni et al., 2005; Rassoulpour et al., 2005) and, in addition, demonstrate for the first time that this effect is concentration-dependent (30-1000 nM). Furthermore, the present findings provide new *in vivo* evidence that KYNA also induces a parallel and concentration-dependent decrease in striatal GABA levels. For both neurotransmitters the inhibitory effect was observed at a concentration of 100 nM used in other studies, and was maximal at 300 nM.

Since KYNA acts as a non-competitive antagonist of the α7nAChRs, from these data it can be reasonably proposed that the reduction of extracellular glutamate and GABA levels by low concentrations of KYNA could be mediated by these receptors. In according with these results, previous *in vivo* microdialysis studies in rodents revealed that even minor elevations in KYNA levels cause a reduction in extracellular glutamate by inhibiting the α7nAChRs located on glutamatergic nerve terminals (Carpenedo et al., 2001; Rassoulpour et al., 2005; Konradsson-Geuken et al., 2010; Wu et al., 2010). Furthermore, an α7nAChR-mediated inhibition of striatal dopamine levels following KYNA perfusion, has also been reported (Wu et al., 2007). A KYNA-induced inhibition of GABA release triggered by α7nAChR activation in hippocampal cultures has also been demonstrated (Lopes et al., 2007).

The modulation of neurotransmitter release by presynaptic nAChRs is the most prevalent and well-studied nicotinic role in the central nervous system. It is well established that the release of many different neurotransmitters is increased by the activation of nAChRs (McGehee and Role, 1995; Role et al., 1996; Wonnacott,

1997; Jones et al., 1999; McGehee et al., 1995; Gray et al., 1996; Albuquerque et al., 1997; Alkondon et al., 1997; Lena and Changeux, 1997; Picciotto et al., 1998; Guo et al., 1998; Radcliffe and Dani, 1998; Luetje 2004; Sher et al., 2004). Consistently, exogenous application of a nicotinic agonist often induces an increase while a nicotinic antagonist induces a decrease in acetylcholine, glutamate, dopamine and norepinephrine release. nAChRs seem to play a role also in the modulation of GABA release. In particular, the nAChR $\alpha 4$ and $\beta 2$ types are the most common ones and are widely expressed in the mammalian brain, including the striatum (Wada et al., 1989; Colquhoun and Patrick, 1997). The $\alpha 7$ subunit-containing nAChRs are the next most common (Seguela et al., 1993). Recent electrophysiological data have demonstrated the presence of nAChRs on GABAergic interneurons in the striatum although the subtypes involved in this effect remain unknown (De Rover et al. 2000; Koos and Tepper, 2002). Other studies support the presence of $\alpha 7$nAChRs on striatal cholinergic interneurons (Azam et al. 2003) as well as on GABAergic interneurons or cell bodies (Kulak et al., 2004). Thus, the localization of $\alpha 7$nAChRs into the striatum is consistent with the hypothesis that KYNA can modulate striatal transmission by acting on these receptors. This view is supported by the data we obtained from the co-application of galantamine (5 µM), that acts as a positive allosteric modulator of the $\alpha 7$nAChRs, with KYNA 100 nM. Interestingly, the intrastriatal galantamine perfusion modestly increased both glutamate and GABA levels. These effects could be due to the positive allosteric action on $\alpha 7$nAChRs by galantamine, which could lead to an increased acetylcholine-induced excitatory modulation of glutamate and GABA levels. This finding is consistent with previous data (Santos et al., 2002) suggesting that galantamine, by acting on presynaptic nAChRs, facilitates glutamatergic and GABAergic neurotransmission. Nicotinic allosteric potentiating ligands, including galantamine, physostigmine, and codeine, effectively increase αn7AChRs activation at subsaturating agonist concentrations (Pereira et al., 2002). Galantamine is currently used to treat mild-to-moderate Alzheimer's disease (Corey-Bloom, 2003) and has also been tested as an adjuvant therapy to improve cognitive function in SZ (Norén et al., 2006; Schubert et al., 2006). Although galantamine is recognized as a weak reversible cholinesterase inhibitor, its nicotinic allosteric potentiating ligand action seems to be an important determinant of its clinical effectiveness (reviewed in Corey-Bloom,

2003; Maelicke and Albuquerque, 1996; Pereira et al., 2002). Acting primarily as a nicotinic allosteric potentiating ligand, galantamine improves synaptic transmission and decreases neurodegeneration, two effects essential for its cognition-enhancing properties (Santos et al., 2002; Dajas-Bailador et al., 2003; Arias et al., 2004; Kihara et al., 2004; Zhang et al., 2004). Thus, it has been reported that at a concentration favoring its nicotinic allosteric potentiating ligand action, galantamine also increased the net charge of choline-evoked on inhibitory postsynaptic currents, IPSCs (i.e. GABA release) triggered by activation of αn7AChRs present on GABAergic hippocampal neurons (Lopes et al., 2007).

More importantly, the present results demonstrate that the co-application of galantamine and KYNA fully prevents the KYNA-induced reduction in both glutamate and GABA levels. This finding is compatible with the hypothesis that these effects were mediated by KYNA's actions at the α7nAChRs. In line with a previous study (Lopes et al., 2007), this observation also provides evidence to support the functional relevance of the antagonistic interactions between the two ligands at α7nAChRs *in vivo*. In fact, superimposition of the lowest energy conformers of galantamine and KYNA revealed a very good fit and shed some light on structural differences that could explain the opposite actions that result from the interactions of the two compounds with the allosteric potentiating ligand-binding region on α7nAChRs (Lopes et al., 2007). Other studies, performed in the rat PFC, demonstrated the ability of galantamine to prevent both neurochemical and cognitive impairments produced by KYNA (Alexander et al. 2012). However, we cannot exclude that the ability of galantamine to weakly increase the extracellular glutamate and GABA levels could contribute to its action against KYNA-induced effects.

To further support the relevance of the role that KYNA plays in regulating striatal glutamate and GABA levels, the present study also demonstrates that the specific inhibition of kynurenate synthesis by local perfusion with ESBA increased both neurotransmitters in the striatum of awake rats. In this context, it is worth noting that previous studies have demonstrated that local PFC perfusion of the selective KAT-II inhibitor ESBA causes a reduction in extracellular KYNA levels associated with a concomitant increase in extracellular glutamate (Zmarowski et al., 2009; Wu et al., 2010; Konradsson-Geuken et al., 2010). Furthermore, in the rat striatum, ESBA reduces extracellular KYNA levels and this effect is accompanied by an

increase in extracellular dopamine levels (Amori et al. 2009). Thus, our study supports the notion that reductions in striatal KYNA formation are functionally significant *in vivo*. In particular, it seems likely that, in the present study, ESBA increased glutamate and GABA levels by reducing endogenous KYNA levels. This view is further supported by the demonstration that when co-infused with KYNA (100 nM), ESBA failed to affect extracellular glutamate and GABA levels. Interestingly, unpublished results indicated that ESBA-induced increase in extracellular glutamate and GABA levels was also blocked by its co-perfusion with a lower (*i.e.* by itself ineffective) KYNA concentration (30 nM). Taken together, these data indicate the existence in the striatum of an inhibitory tone exerted by endogenous KYNA on extracellular glutamate and GABA levels.

Since our investigation has been conducted using microdialysis, it is also important to consider that dialysate basal extracellular glutamate and GABA levels are derived from both neuronal and glial sources (vesicular or non-vesicular pools) (Timmerman and Westerink, 1997; Baker et al., 2002). Neuronal glutamate levels in the striatum mainly derived from cortical and thalamic neuron terminals (Sirinathsinghji and Heavens, 1989; Parent and Hazrati, 1995), whereas extracellular striatal GABA levels derived in part from local interneurons and the axon collaterals of the striopallidal and strionigral projection neurons (Sirinathsinghji and Heavens, 1989; Parent and Hazrati, 1995). The evidence that, under the present experimental conditions, TTX (2 µM), a well-known sodium channel blocker, induced only a modest reduction in basal extracellular levels of glutamate and GABA, suggests that these levels are derived from both neuronal and glial sources. Various studies previously reported that striatal glutamate and GABA levels in dialysates are virtually TTX-insensitive and unaffected by the depletion of extracellular Ca^{++} levels (Timmerman and Westerink, 1997). However other studies found a partial TTX-sensitivity of basal striatal dialysate glutamate and GABA levels (Osborne et al., 1990; Dawson et al., 1995). Based on the TTX-sensitivity of glutamate and GABA levels under our experimental conditions, it can be hypothesized that KYNA exerts its effects on the two neurotransmitters by modulating exocytotic processes. However, in view of the clear-cut reduction of glutamate and GABA levels seen with KYNA *vs* TTX, a decrease of glial glutamate and GABA levels is likely involved in the decline of these extracellular aminoacid levels seen after KYNA perfusion. The demonstration that α7nAChRs are also

localized on astrocytes (Pakkannen et al., 2005), supports the possibility that glia may likewise play a role in the action of KYNA on extracellular glutamate and GABA levels. This view is further reinforced by the observation that when we perfused TTX (2 µM) in combination with ESBA, we observed a significant, but partial, reduction of the ESBA-induced increase in extracellular glutamate and GABA levels. It could be proposed that TTX, by deleting the endogenous cholinergic tone on glutamate and GABA neurons, renders ineffective the ESBA-induced counteraction of the inhibitory tone exerted by endogenous KYNA, through α7nAChRs, on extracellular glutamate and GABA levels.

Taken together, the present experiments clearly indicate that fluctuations in the endogenous KYNA levels tonically regulate extracellular glutamate and GABA levels in the rat striatum, possibly by acting on local α7nAChRs. Concerning a possible mechanism of action, it seems likely that KYNA-induced modulation of striatal glutamate levels is mediated by α7nAChRs on cortical glutamatergic afferents (Pakkanen et al., 2005). It could be postulated that these presynaptic receptors, which can modulate striatal glutamate levels (Kaiser and Wonnacott, 2000; Marchi et al., 2002), are regulated by astrocyte-derived KYNA, possibly through volume transmission (Agnati and Fuxe 2000, Del Arco et al., 2003; Wu et al., 2007; Amori et al., 2009). Furthermore, astrocytes, which can release glutamate by stimulation of α7nAChRs (Sharma and Vijayaraghavan, 2001; Patti et al., 2007), can contribute to this effect. In view of this, it could also be postulated that KYNA decreases striatal GABA levels either directly, by interacting with α7nAChRs located on GABAergic interneurons, or indirectly by reducing glutamatergic excitatory modulation of striatal GABA levels (Figure 35A). In fact, numerous studies suggest that a modulation of glutamate release in the striatum by α7nAChRs, in turn affects additional neurotransmitter systems including monoamines (Kaiser and Wonnacott, 2000; Barik and Wonnacott, 2006) and GABA (Dani and Bertrand, 2007). Thus, the activation of α7nAChRs situated on glutamatergic afferents is known to modulate extracellular levels of dopamine (Segovia et al., 1997) and previous findings suggested that, mainly through presynaptically situated AMPA receptors, KYNA-induced reduction in striatal glutamate in turn affects striatal dopamine release (Amori et al., 2009). In view of these findings, it seems likely that fluctuations in KYNA indirectly regulate

extracellular GABA levels in the striatum by initially targeting α7nAChRs on glutamatergic nerve terminals or astrocytes (Figure 35B).


Figure 35. Schematic representation of the possible mechanisms (*i.e.* direct, Panel A; and indirect, Panel B) underlying the kynurenic acid (KYNA)-induced modulation of striatal extracellular GABA levels. For details see text. L-KYN = L-kynurenine, a KYNA bioprecursor.

For the sake of clarity, it should be noted that in recent studies KYNA has been also proposed as the endogenous agonist of the GPR35 (*see* Introduction). This receptor is expressed in neurons and glia cells and is especially abundant in the dorsal root ganglia as well as in cells of the immune system (Wang et al., 2006). The binding of KYNA to GPR35 has been hypothesized to decrease intracellular calcium with a consequent reduction of the release of the excitatory amino acids from glia cells (Moroni et al., 2012). However, controversy remains to be solved as to whether it reaches sufficient tissue concentrations to be the endogenous ligand (Mackenzie et al., 2011). Although this finding is still in its infancy and the existence of GPR35 into the striatum has not been demonstrated, it could be speculated that also this mechanism is involved in the observed KYNA-induced reduction of striatal glutamate and GABA levels.

Concerning the possible relevance of the present study, the ability of endogenous KYNA to reduce extracellular glutamate levels, together with its antioxidant properties, which are related to the compound's ability to scavenge hydroxyl, superoxide anion and other free radicals, support its role as a neuroprotective agent. In fact, it is well known that under pathological conditions, the excessive stimulation of NMDA receptors leads to an excess of intracellular calcium to produce excitotoxicity, a toxic mechanism currently involved in cell death in several disorders of the brain (including Alzheimer's disease, stroke, Huntington's disease and Parkinson's disease). In these pathologies an increased glutamatergic transmission and mitochondrial metabolic disturbances are primary mechanisms turning neuronal cells more sensitive to excitotoxic damage (Kemp and McKernan, 2002). Interestingly, decreased KYNA concentrations have been reported in the SN *pars compacta*, putamen and frontal cortex of patients with Parkinson's disease and have been related to the progression of the pathology. Decreased KYNA levels have been found in the CSF, striatum and neocortex of patients with Huntington's disease. Furthermore, the activity of KAT, the enzyme responsible for KYNA biosynthesis, has been demonstrated to be reduced in the striatum of Huntington's disease patients (Beal et al., 1990; Jauch et al., 1995; Guidetti et al., 2004). These alterations have been suggested to be related to the development of the disease. Other reports claim increased formation of neurotoxic kynurenines such as QUIN and 3-HK levels and marked decreases in KYNA/QUIN and KYNA/3-HK ratios within the striatum of patients with low-grade Huntington's

disease. Concordant observations have been made in the murine models of the disease. Taken together, these findings indicate that the pharmacological manipulations to utilize the anti-excitotoxic properties of KYNA could be effective to confer neuroprotection. In line with this view, at preclinical levels the pharmacological elevation of endogenous astrocytic KYNA release has been proven to be neuroprotective against striatal QUIN toxicity. The genetic ablation of KMO, the activation of which results in a harmful shift in kynurenine metabolism towards the formation of toxic metabolites, has also been demonstrated to be neuroprotective in transgenic yeast and Drosophila models of the disease. More recently, the intraperitoneal application of a novel KYNA analogue *N*-(2-*N*,*N*-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride resulted in a remarkable (30%) increase in survival and improvement in motor performance in a transgenic murine model of Huntington's disease. Although these "kynurenergic approaches" to contrast neurodegeneration appear to be promising, the most important question that should be addressed is whether the elevation of KYNA levels that achieve neuroprotective effects at least in part through suppressing synaptic glutamate release can be utilized without compromising cognitive functions. Indeed, endogenous elevation of KYNA and the subsequent suppression in the presynaptic release of glutamate, and also GABA levels, have been linked to decreased performance in a wide range of hippocampus-dependent tasks experimentally. Interestingly, also the striatum could be involved in these deleterious effects of increased KYNA levels. In fact, an abnormal disposition of striatal neurotransmitters, including acetylcholine, dopamine, glutamate and GABA, is known to play a major role in the dysfunction of cortico-basal ganglia-thalamo-cortical circuit, which underlies key aspects of cognition (Havekes et al., 2011). In this context, recent studies support the hypothesis that the striatum is involved in initiating the cognitive deficits associated to SZ (Simpson et al. 2010), a mental illness in which a dysfunction in KP seems to play a relevant role (see below).

5.2 Prefrontal cortex

The PFC contains glutamatergic and GABAergic afferents (Gritti et al., 2003; Hur and Zaborszky, 2005; Rotaru et al., 2005) as well as intrinsic glutamatergic pyramidal neurons and GABAergic interneurons, which are connected by multiple signaling mechanisms (Tseng and O'Donnell, 2004; Povysheva et al., 2008; DeFilipe et al., 2013). Although the complexity of these anatomical arrangements has so far precluded a comprehensive understanding of the functional interactions between GABAergic and glutamatergic mechanisms in the PFC, it is noteworthy that pharmacological manipulations frequently lead to parallel changes in the extracellular levels of GABA and glutamate in this brain region (Sanz et al., 1997; Abekawa et al., 2000; Frantz et al., 2002; Yamamura et al., 2009). While exceptions have been noted (Frantz et al., 2002; Pistis et al., 2002), the KYNA-related fluctuations in the levels of these two major neurotransmitters in the present study were also remarkably similar in both qualitative and quantitative terms. In fact, our parallel determination of GABA and glutamate in the same microdialysate fractions revealed additional features of the recently described bi-directional modulation of extracellular glutamate levels by endogenous KYNA in the rat brain (Konradsson-Geuken et al., 2010; Wu et al., 2010; Pocivavsek et al., 2011). Thus, we showed here for the first time that local perfusion of nanomolar KYNA reduces glutamate levels in the PFC concentration-dependently, and that this effect was not duplicated by either 7-Cl-KYNA or CNQX. Moreover, specific inhibition of KYNA neosynthesis caused an increase in extracellular glutamate levels, and this effect was prevented by the addition of 30 nM KYNA to the perfusion medium. Finally, co-application of galantamine prevented the reduction of glutamate levels by KYNA. Taken together, these results demonstrate a close coupling between the effects of endogenous KYNA on extracellular GABA and glutamate levels in the PFC.

Our pharmacological data indicate that glutamate receptors are not the primary target of endogenous KYNA in the rat PFC *in vivo*, as demonstrated by the failure of the selective NMDA receptor antagonist 7-Cl-KYNA or the selective AMPA/kainate antagonist CNQX to duplicate the effect of KYNA. Possible alternatives include the α7nAChRs (Hilmas et al., 2001), GPR35 (Wang et al., 2006), and the aryl hydrocarbon receptor (DiNatale et al., 2010), all of which recognize KYNA at concentrations in the high nanomolar to low micromolar range.

As α7nAChRs in the PFC, like in other brain regions (McGehee et al., 1995; Marchi et al., 2002), are located on glutamatergic nerve terminals where they can control glutamate release (Gioanni et al., 1999; Dickinson et al., 2008), and as α7nAChRs are expressed and functional in PV-positive (*i.e.* GABAergic) cortical interneurons (Lubin et al., 1999; Alkondon et al., 2000; Krenz et al., 2001), these receptors are especially attractive candidates. The present demonstration that galantamine, which activates an allosteric site of the α7nAChR that overlaps with the site targeted by KYNA (Lopes et al., 2007), neutralizes the effects of KYNA also appears to favor this interpretation. However, in line with previous findings (Konradsson-Geuken et al., 2010; Wu et al., 2010), and in contrast to the striatum (Beggiato et al., 2013), we failed to observe any significant increase in local extracellular glutamate and GABA levels when galantamine alone was perfused into the PFC. Thus, under basal conditions, glutamatergic and GABAergic neurotransmission in the PFC may be less sensitive to α7nAChRs allosteric potentiation by galantamine than in the striatum and in other cortical areas (Alkondon et al., 2009; Aracri et al., 2010). More generally and of note, KYNA does not inhibit α7nAChR function in all situations (Arnaiz-Cot et al., 2008) so that definitive identification of its *in vivo* target(s) clearly requires further detailed scrutiny (see Albuquerque and Schwarcz, 2013, for review).

In the PFC, the majority (65%) of α7nAChRs is associated with dendrites and dendritic spines, which are postsynaptic to excitatory axon terminals devoid of α7nAChRs (Duffy et al., 2009). These nerve endings, which form a dense network of asymmetric axo-dendritic synapses onto prefrontal interneurons, may derive from extrinsic neurons (Rotaru et al., 2005). Activation of α7nAChRs can therefore modulate cortical GABAergic neurotransmission not only indirectly, i.e. *via* glutamate, but also directly (Thomsen et al., 2009). In addition, since α7nAChRs in the PFC are also localized on non-glutamatergic nerve endings (Duffy et al., 2009), other, complex mechanisms involving α7nAChRs likely also play a role in the regulation of prefrontal GABAergic and glutamatergic neurotransmission (Couey et al., 2007; Aracri et al., 2010).

The role of astrocytes, which themselves carry functional α7nAChRs (Duffy et al., 2011; Shen and Yakel, 2012) and GPR35 receptors (Berlinguer-Palmini et al., 2013), and are known to control cortical GABA and glutamate neurons (Patti et al., 2007; Wang et al., 2013), deserves special attention in the context of our study.

Furthermore in the cortex as well as in other brain regions, these glial cells contain the vast majority of KAT II, the major enzyme responsible for the synthesis of rapidly mobilizable KYNA in the brain (Guidetti et al., 2007). Upon neosynthesis, astrocyte-derived KYNA is rapidly liberated into the extracellular milieu where it can serve as a neuromodulator (Turski et al., 1989; Schwarcz et al., 2012). Here we took advantage of this anatomical arrangement to test the hypothesis that a reduction in KYNA formation will also influence extracellular glutamate and GABA concentrations, albeit in the opposite direction as perfusion with KYNA itself. In other words, our experiment was designed to investigate the possible role of endogenous KYNA as a bona fide regulator of extracellular glutamate and GABA levels in the PFC, as shown in the striatum. To this end, we inhibited astrocytic KYNA production by reverse dialysis of the selective KAT II inhibitor ESBA (Pellicciari et al., 2008) and confirmed the specificity of the observed increase in extracellular glutamate and GABA levels by neutralizing the effect using co-perfusion of ESBA with minute amounts of KYNA.

KP metabolism is impaired, resulting in elevated brain and CSF levels of KYNA in psychiatric diseases, including SZ (Erhardt et al., 2001; Schwarcz et al., 2001; Miller et al., 2006; Sathyasaikumar et al., 2011; Wonodi et al., 2011; Lavebratt et al., 2013) and bipolar disorder (Olsson et al., 2012), as well as in relevant animal models (Miura et al., 2011; Pocivavsek et al., 2012; McTighe et al., 2013). The bi-directional modulation of prefrontal GABA and glutamate levels by KYNA is therefore not only of obvious physiological relevance but may also be pertinent to the etiology of attentional and cognitive deficits observed in SZ and other brain diseases. Electrophysiological and imaging studies in patients, as well as post-mortem assessments of brain tissues, have provided evidence for pathophysiologically significant impairments in both GABAergic and glutamatergic neurotransmission in psychiatric disorders. In addition, cortical GABA dysfunction is one of the most consistently observed abnormality in SZ (Coyle, 2004; Volk and Lewis, 2010; Gonzalez-Burgos and Lewis, 2012). As defective cortical GABA and glutamate function substantively impairs cognitive processes (Floresco et al., 2009; Goto et al., 2010; Pehrson et al., 2013; Rompala et al., 2013), and as increases in brain KYNA levels in rats adversely affect a variety of cognitive functions (Chess et al., 2007; Pocivavsek et al., 2011; Alexander et al., 2012), it is

tempting to hypothesize a causal connection between these neurochemical and behavioral phenomena.

Notably, an activation of astrocytes in the PFC of individuals with psychotic illness has recently been reported (Feresten et al., 2013) and may be related to the increase in prefrontal KYNA levels seen in SZ (Schwarcz et al., 2001). Regardless of this potential causal link between structure and function, and assuming that our data can be extrapolated to humans, the results of the present study suggest that a down-regulation of KYNA formation in astrocytes may not only boost cognitive functions in normal individuals, as suggested by the enhanced cognitive behaviors seen in KAT II-deficient mice (Potter et al., 2010) and following pharmacological KAT II inhibition in healthy rats (Pocivavsek et al., 2011), but may provide special benefits in the treatment of cognitive deficits in SZ and other brain diseases. Such improvements would be in line with the ability of the specific KAT II inhibitor ESBA to elevate the extracellular levels of both GABA and glutamate in the PFC shown here. Ongoing studies in the laboratories of Prof. R. Schwarcz are designed to reduce KYNA neosynthesis, and thus elevate extracellular GABA and glutamate levels in the PFC, by administering the novel, orally active KAT II inhibitor BFF-816, which has shown promising effects in preliminary experiments (Wu et al., in press).

5.3. Conclusion

The ongoing discoveries in the KP field are revealing that this highly conserved metabolic machinery plays important regulatory functions in the mammalian brain. Excitingly, as we explore the largely unknown role(s) of kynurenines in cell biology, we are likely to uncover the functional significance of distinct intracellular processes they might influence. As widely reported in this dissertation, changes in the levels of circulating kynurenine under pathological conditions can either increase (in neurological disorders) or reduce (in SZ) the ratio between neurotoxic and neuroprotective KP metabolites in the brain. Although the recent progress in understanding the physiopathological role that KYNA could play in the CNS, new information is needed to confidently predict the desired physiological effects or clinical improvements caused by pharmacological manipulations of this "neuroactive kynurenine" brain levels. The work described in this dissertation

contributes to improve our understanding of endogenous KYNA functions in the CNS, and especially in cognitive functions. The main finding we obtained is the demonstration that fluctuations in KYNA levels bi-directionally modulate striatal and prefrontal GABA and glutamate levels and these effects may be pertinent to the etiology of attentional and cognitive deficits observed in SZ and other brain diseases. In addition, the ability of the compound to reduce striatal glutamate levels at physiological concentrations, may be relevant to further support the protective action that KYNA exerts against neurodegenerative diseases. Thus, the manipulation of KYNA levels and, in particular the ratio between KYNA and "neurotoxic" kynurenines seem to be promising for the therapy of different CNS disorders (Figure 36). However, further studies are necessary to confirm that the interventions with specific "kynurenergic" drugs must be carefully tailored to achieve the intended benefit and avoid harmful outcomes. If the contribution of KYNA in the pathogenesis of CNS disorders will be confirmed along with the possibility to safely manipulate endogenous KYNA levels, kynurenergic manipulations will offer novel therapeutic tools for these severe debilitating diseases in the future.

Figure 36. Targeting brain kynurenines pharmacologically: focus on KAT II and KMO. As KAT II and KMO are directly responsible for the formation of KYNA and 3-HK, respectively, specific inhibitors of these enzymes can be used to manipulate the ratio between these two neuroactive metabolites pharmacologically. Increases in the KYNA:3-HK ratio are desirable in neurodegenerative diseases such as Huntington's disease, which present with an excess of neurotoxic 3-HK (and QUIN) in the brain. Conversely, lowering of the KYNA:3-HK ratio in the brain will improve cognitive capabilities, providing special benefits in diseases such as schizophrenia, which show enhanced brain levels of KYNA 140. In the normal brain, fluctuations in the KYNA:3-HK ratio will have moderate effects on neuronal viability and cognition, limited to the physiological range. Pharmacological interventions with specific "kynurenergic" agents, such as KAT II or KMO inhibitors, should therefore be tailored to achieve the intended benefits and minimize potentially harmful consequences. The gray areas indicate transition zones between the physiological range and pathologies.

6. REFERENCES

Abekawa T, Ohmori T, Ito K, Koyama T (2000). D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res. 867, 250-254.

Agnati LF and Fuxe K (2000). Volume transmission as a key feature of information handling in the central nervous system possible new interpretative value of the Turing's B-type machine. Prog Brain Res. 125:3-19.

Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry. 156(10):1580-9.

Albin RL, Young AB, Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12(10):366-75.

Albuquerque EX and Schwarcz R (2013). Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 85(8):1027-32. doi: 10.1016/j.bcp.2012.12.014.

Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009). Mammalian nicotinic acetilcholine receptors: from structure to function. Physiol Rev 89:73-120.

Albuquerque EX, Pereira EF, Braga MF, Matsubayashi H, Alkondon M (1998). Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine. Toxicol Lett. 102-103:211-8.

Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A (1997). Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 280(3):1117-36.

Alexander KS, Wu HQ, Schwarcz R, Bruno JP (2012). Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl.) 220, 627-637.

Alexander GE, DeLong MR, Strick PL (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 9:357-81.

Alkondon M, Aracava Y, Pereira EF, Albuquerque EX (2009). A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus. J Pharmacol Exp Ther. 328(1):69-82. doi: 10.1124/jpet.108.146068.

Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX (2000). Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci. 20, 66-75.

Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX (1997). Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. 9(12):2734-42.

Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R (2009). Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159, 196-203.

Aracri P, Consonni S, Morini R, Perrella M, Rodighiero S, Amadeo A, Becchetti A (2010). Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex. Cereb Cortex. 20, 1539-1555.

Araque A, Sanzgiri RP, Parpura V, Haydon PG (1999). Astrocyte-induced modulation of synaptic transmission. Can J Physiol Pharmacol. 77(9):699-706.

Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, López MG (2004). Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46(1):103-14.

Arnaiz-Cot JJ, Gonzáles JZ, Sobrado M, Baldelli P, Carbone E, Gandía L, García AG, Hernández-Guijo JM (2008). Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci. 27, 1097-1110.

Azam L, Winzer-Serhan U, Leslie FM (2003). Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. Neuroscience 119, 965-977.

Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW (2002). The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci. 22, 9134-9141.

Banerjee J, Alkondon M, Pereira EF, Albuquerque EX (2012). Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J. Pharmacol. Exp. Ther. 341, 500-509.

Baran H and Schwarcz R (1990). Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J Neurochem. 55(3):738-44.

Barch DM (2005). The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol. 1:321-53.

Barik J and Wonnacott S (2006). Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol. 69(2):618-28.

Bartos M, Vida I, Jonas P (2007). Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 8, 45-56.

Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res. 104(1-3):108-20. doi: 10.1016/j.schres.2008.06.012

Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990). Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem. 55(4):1327-39

Beggiato S, Antonelli T, Tomasini MC, Tanganelli S, Fuxe K, Schwarcz R, Ferraro L (2013). Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur J Neurosci. 37, 1470-1477.

Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, Dugan LL (2007). Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 318(5856):1645-7.

Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 13(1):76-83. doi: 10.1038/nn.2447.

Bencherif M, Stachowiak MK, Kucinski AJ, Lippiello PM (2012). Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med Hypotheses 78(5):594-600. doi: 10.1016/j.mehy.2012.01.035.

Bennett BD and Bolam JP (1994). Synaptic input and output of parvalbumin-immunoreactive neurons in the neostriatum of the rat. Neuroscience. 62(3):707-19.

Berlinguer-Palmini R, Masi A, Narducchi R, Cavone L, Maratea D, Cozzi A, Sili M, Moroni F, Mannaioni G (2013). PloS One. 8, e82180.

Bernard V and Bolam JP (1998). Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur J Neurosci. 10(12):3721-36.

Bernard V, Somogyi P, Bolam JP (1997). Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. J Neurosci. 17(2):819-33.

Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000). Synaptic organisation of the basal ganglia. J Anat. 196 (Pt 4):527-42.

Braidy N, Guillemin GJ, Grant R (2011). Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons. Int J Tryptophan Res. 4:29-37. doi: 10.4137/IJTR.S7052.

Buchsbaum MS (1990). The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull. 16(3):379-89.

Carlsson M and Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13(7):272-6.

Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F (2001). Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 13(11):2141-7.

Castner SA, Smagin GN, Piser TM, Wang Y, Smith JS, Christian EP, Mrzljak L, Williams GV (2011). Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors. Biol Psychiatry. 69(1):12-8. doi: 10.1016/j.biopsych.2010.08.006.

Ceresoli-Borroni G, Guidetti P, Schwarcz R (1999). Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. J Neural Transm. 106(3-4):229-42.

Changeux JP, Bertrand D, Corringer PJ, Dehaene S, Edelstein S, Léna C, Le Novère N, Marubio L, Picciotto M, Zoli M (1998). Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res Brain Res Rev. 26(2-3):198-216.

Chess AC, Simoni MK, Alling TE, Bucci DJ (2007). Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 33(3):797-804.

Chess AC and Bucci DJ (2006). Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 170(2):326-32.

Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F (1995). Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem. 65(3):1176-83

Clements JD and Westbrook GL (1991). Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron 7(4):605-13.

Colquhoun LM and Patrick JW (1997). Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmacol. 39:191-220.

Corey-Bloom J (2003). Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 57(3):219-23.

Couey JJ, Meredith RM, Spijker S, Poorthuis RB, Smit AB, Brussaard AB, Mansvelder HD (2007). Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron. 54, 73-87.

Coyle JT (2004). The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol. 68(8):1507-14.

Csillik AE, Okuno E, Csillik B, Knyihár E, Vécsei L (2002). Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex. 12(11):1193-201.

Cull-Candy S, Brickley S, Farrant M (2001). NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 11(3):327-35.

Dajas-Bailador FA, Heimala K, Wonnacott S (2003). The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol. 64(5):1217-26.

Dani JA and Bertrand D (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 47:699-729.

Dani JA and Harris RA (2005). Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci. 8(11):1465-70.

Dawson R Jr, Patterson TA, Eppler B (1995). Endogenous excitatory amino acid release from brain slices and astrocyte cultures evoked by trimethyltin and other neurotoxic agents. Neurochem Res. 20(7):847-58.

DeFelipe J, López-Cruz PL, Benavides-Piccione R, Bielza C, Larrañaga P, Anderson S, Burkhalter A, Cauli B, Fairén A, Feldmeyer D, Fishell G, Fitzpatrick, D Freund TF, González-Burgos G, Hestrin S, Hill S, Hof PR, Huang J, Jones EG, Kawaguchi Y, Kisvárday Z, Kubota Y, Lewis DA, Marín O, Markram H, McBain CJ, Meyer HS, Monyer H, Nelson SB, Rockland K, Rossier J, Rubenstein JL, Rudy B, Scanziani M, Shepherd GM, Sherwood CC, Staiger JF, Tamás G, Thomson A, Wang Y, Yuste R, Ascoli GA (2013). New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat Rev Neurosci. 14, 202-216.

DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13(7):281-5.

Del Arco A, Segovia G, Fuxe K, Mora F (2003). Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions? J Neurochem. 85(1):23-33.

De Rover M, Schoffelmeer ANM, Kits KS (2000). Cholinergic modulation of GABAergic and glutamatergic synaptic transmission in the nucleus accumbens (NAC) shell of the rat. The 10th Neuropharmacology Conference Abstracts, p 169.

Descarries L, Gisiger V, Steriade M (1997). Diffuse transmission by acetylcholine in the CNS. Prog Neurobiol. 53(5):603-25.

Deutsch SI, Rosse RB, Schwartz BL, Weizman A, Chilton M, Arnold DS, Mastropaolo J (2005). Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia. Isr J Psychiatry Relat Sci. 2005;42(1):33-44.

Dickinson JA, Kew JN, Wonnacott S (2008). Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol. 74, 348-359.

DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010). Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 115, 89-97.

Duffy AM, Fitzgerald ML, Chan J, Robinson DC, Milner TA, Mackie K, Pickel VM (2011). Acetylcholine α7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Synapse. 65, 1350-1367.

Duffy AM, Zhou P, Milner TA, Pickel VM (2009). Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse. Neuroscience. 161, 1091-1103.

Eastman CL and Guilarte TR (1989). Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 495(2):225-31.

Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004). Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 56(4):255-60.

Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 313, 96-98.

Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001). Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci. 21(20):7993-8003.

Feresten AH, Barakauskas V, Ypsilanti A, Barr AM, Beasley CL (2013). Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr Res. 150, 252-257.

Floresco SB, Zhang Y, Enomoto T (2009). Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res. 204, 396-409.

Foster AC, Vezzani A, French ED, Schwarcz R (1984). Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 48(3):273-8.

Frantz K, Harte M, Ungerstedt U, O' Connor WT (2002). A dual probe characterization of dialysate amino acid levels in the medial prefrontal cortex and ventral tegmental area of the awake freely moving rat. J Neurosci Meth. 119, 109-119.

Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV (1998). Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci.18(20):8228-35.

Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 94(2):587-92.

Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991). Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 56(6):2007-17.

Ge S and Dani JA (2005). Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J Neurosci. 25(26):6084-91.

Giles GI, Collins CA, Stone TW, Jacob C (2003). Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem Biophys Res Commun. 300(3):719-24.

Gioanni Y, Rougeot C, Clarke PB, Leopouśe C, Thierry AM, Vidal C (1999). Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci. 11, 18-30.

Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, Velligan DI (2005). Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp. 25(1):60-9.

Gold JM (2004). Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 72(1):21-8.

Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 174(1):3-16.

Goldman-Rakic PS (1995). More clues on "latent" schizophrenia point to developmental origins. Am J Psychiatry. 152(12):1701-3.

Gonzalez-Burgos G and Lewis DA (2012). NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull. 38, 950-957.

Gonzalez-Burgos G, Hashimoto T, Lewis DA (2010). Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep. 12(4):335-44. doi: 10.1007/s11920-010-0124-8.

Gonzalez-Burgos G and Lewis DA (2008). GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 34(5):944-61. doi: 10.1093/schbul/sbn070.

Goto Y, Yang CR, Otani S (2010). Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry. 67, 199-207.

Gramsbergen JB, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P, Schwarcz R (1997). Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem. 69(1):290-8.

Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996). Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713–16.

Graybiel AM (2008). Habits, rituals, and the evaluative brain. Annu Rev Neurosci. 2008;31:359-87. doi: 10.1146/annurev.neuro.29.051605.112851.

Graybiel AM (1998). The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem. 70(1-2):119-36.

Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 153(3):321-30

Grilli M, Raiteri L, Patti L, Parodi M, Robino F, Raiteri M, Marchi M (2006). Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br J Pharmacol. 149, 724-732.

Gritti I, Manns ID, Mainville L, Jones BE (2003). Parvalbumin, calbindin, or calretinin in cortically projecting and GABAergic, cholinergic, or glutamatergic basal forebrain neurons of the rat. J Comp Neurol. 458, 11-31.

Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R (2007). Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem. 102(1):103-11.

Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 17(3):455-61.

Guidetti P and Schwarcz R (1999). 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci. 1999 (11):3857-63.

Guidetti P, Eastman CL, Schwarcz R (1995). Metabolism of [5-3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J Neurochem. 65(6):2621-32.

Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001). Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 78(4):842-53.

Guillin O, Abi-Dargham A, Laruelle M (2007). Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 78:1-39.

Guo JZ, Tredway TL, Chiappinelli VA (1998). Glutamate and GABA release are enhanced by different subtypes of presynaptic nicotinic receptors in the lateral geniculate nucleus. J. Neurosci. 18:1963–69.

Halassa MM, Fellin T, Haydon PG (2007). The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med. 13(2):54-63.

Hashimoto T, Arion D, Unger T, Maldonado-Avilés JG, Morris HM, Volk DW, Mirnics K, Lewis DA (2008). Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13(2):147-61.

Havekes R, Abel T, Van der Zee EA (2011). The cholinergic system and neostriatal memory functions. Behav Brain Res. 221(2):412-23. doi: 10.1016/j.bbr.2010.11.047.

Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP (1996). Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 320 (Pt 2):595-7.

Hilmas C, Pereira EF, Alcondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001). The brain metabolite kynurenic acid inhibits alpha 7 nicotinic receptor activity and increases non-alpha 7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473.

Homayoun H and Moghaddam B (2006). Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry. 61(5):679-87.

Hur EE and Zaborszky L (2005). Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization study. J Comp Neurol. 483, 351-373.

Jauch D, Urbańska EM, Guidetti P, Bird ED, Vonsattel JP, Whetsell WO Jr, Schwarcz R (1995). Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci. 130(1):39-47.

Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P (2005). Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 48(15):4705-45.

Johnson JW and Ascher P (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325(6104):529-31.

Jones CK, Byun N, Bubser M (2011). Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 37(1):16-42. doi: 10.1038/npp.2011.199.

Jones S, Sudweeks S, Yakel JL (1999). Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 22(12):555-61.

Kaiser S and Wonnacott S (2000). alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol. 58(2):312-8.

Karlin A (2002). Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci. 3(2):102-14.

Kawaguchi Y (1997). Neostriatal cell subtypes and their functional roles. Neurosci Res. 27(1):1-8.

Keefe RS, (2007). Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 68 Suppl 14:8-13.

Kemp JA and McKernan RM (2002). NMDA receptor pathways as drug targets. Nat Neurosci. Suppl:1039-42.

Kemp JM and Powell TP (1971). The synaptic organization of the caudate nucleus. Philos Trans R Soc Lond B Biol Sci. 262(845):403-12.

Kettenmann H and Ransom BR (2004). Neuroglia, 2nd edition: 624.

Kita H (1996). Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations. Neuroscience. 70(4):925-40.

Kleist K (1960). Schizophrenic symptoms and cerebral pathology. J Ment Sci. 106:246-55.

Knowlton BJ, Mangels JA, Squire LR (1996). A neostriatal habit learning system in humans. Science 273(5280):1399-402.

Knowlton BJ, Squire LR, Gluck MA (1994). Probabilistic classification learning in amnesia. Learn Mem. 1(2):106-20.

Konradsson-Geuken A, Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, Pellicciari R, Schwarcz R, Bruno JP (2010). Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169, 1848-1859.

Koós T and Tepper JM (2002). Dual cholinergic control of fast-spiking interneurons in the neostriatum. J Neurosci. 22(2):529-35.

Krenz I, Kalkan D, Wevers A, de Vos RA, Steur EN, Lindstrom J, Pilz K, Nowacki S, Schutz U, Moser N, Witter B, Schroder H (2001). Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins J Chem Neuroanat. 21, 239-246.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51(3):199-214.

Kulak JM and Schneider JS (2004). Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res. 999, 193-202.

Lalonde R and Botez-Marquard T (1998). The neurobiological basis of movement initiation. Rev Neurosci. 8(1):35-54.

Lapper SR, Smith Y, Sadikot AF, Parent A, Bolam JP (1992). Cortical input to parvalbumin-immunoreactive neurones in the putamen of the squirrel monkey. Brain Res. 580(1-2):215-24.

Lavebratt C, Olsson S, Backlund L, Frisén L, Sellgren C, Priebe L, Nikamo P, Träskman-Bendz L, Cichon S, Vawter MP, Osby U, Engberg G, Landén M, Erhardt S, Schalling M (2013). The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2013 Mar 5. doi: 10.1038/mp.2013.11

Léna C and Changeux JP (1998). Allosteric nicotinic receptors, human pathologies. J Physiol Paris. 92(2):63-74.

Léna C and Changeux JP (1997). Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci. 17(2):576-85.

Léna C, Changeux JP, Mulle C (1993). Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci. 13(6):2680-8.

Levin ED, McClernon FJ, Rezvani AH (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 184(3-4):523-39.

Lewis DA and Sweet RA (2007). Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 119(4):706-16. doi: 10.1172/JCI37335.

Lewis DA and Moghaddam B (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 63, 1372-1376.

Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 6(4):312-24.

Lewis DA (1998). Chandelier cells: shedding light on altered cortical circuitry in schizophrenia. Mol Psychiatry. 3(6):468-71, 466-7.

Lewis DA and Anderson SA (1995). The functional architecture of the prefrontal cortex and schizophrenia. Psychol Med. 25(5):887-94.

Lin H, Hsu FC, Baumann BH, Coulter DA, Lynch DR (2014). Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: Implications for neuropsychiatric diseases. Neurobiol Dis. 63:129-40. doi: 10.1016/j.nbd.2013.11.021.

Lopes C, Pereira EF, Wu HQ, Purushottamachar P, Njar V, Schwarcz R, Albuquerque EX (2007). Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther. 322, 48-58.

Lubin M, Erisir A, Aoki C (1999). Ultrastructural immunolocalization of the alpha7 nAChR subunit in guinea pig medial prefrontal cortex. Ann NY Acad Sci. 868, 628-632.

Luetje CW (2004). Getting past the asterisk: the subunit composition of presynaptic nicotinic receptors that modulate striatal dopamine release. Mol. Pharmacol. 65:1333–35.

Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, Carrillo-Mora P, Pedraza-Chaverrí J, Silva-Adaya D, Maldonado PD, Torres I, Pinzón E, Ortiz-Islas E, López T, García E, Pineda B, Torres-Ramos M, Santamaría A, La Cruz VP (2011). On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 33(5):538-47. doi: 10.1016/j.ntt.2011.07.002.

MacDonald JF, Jackson MF, Beazely MA (2006). Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Crit Rev Neurobiol. 18(1-2):71-84.

Machaalani R, Kashi PK, Waters KA (2010). Distribution of nicotinic acetylcholine receptor subunits alpha7 and beta2 in the human brainstem and hippocampal formation. J Chem Neuroanat. 40(3):223-31. doi: 10.1016/j.jchemneu.2010.05.009.

Mackenzie AE, Lappin JE, Taylor DL, Nicklin SA, Milligan G (2011). GPR35 as a Novel Therapeutic Target. Front. Endocrinol. (Lausanne) 2, 68.

Mair RG, Koch JK, Newman JB, Howard JR, Burk JA (2002). A double dissociation within striatum between serial reaction time and radial maze delayed nonmatching performance in rats. J Neurosci. 2002 22(15):6756-65.

Maelicke A and Albquerque EX (1996). New approach to drug therapy in Alzheimer's dementia. Drug Disc Today 1:53–59.

Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M (2002). Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 80, 1071-1078.

Marín O (2012). Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci. 13(2):107-20.

Martin LF and Freedman R (2007). Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 78:225-46.

Mathew SV, Law AJ, Lipska BK, Dávila-García MI, Zamora ED, Mitkus SN, Vakkalanka R, Straub RE, Weinberger DR, Kleinman JE, Hyde TM (2007). Alpha 7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet. 16(23):2921-32.

McGehee DS and Role LW (1995). Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 57:521-46.

McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG (2013). The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS One 8, e62189.

Melendez-Ferro M, Guidetti P, Hoffman GE, Schwarcz R (2005). Immunocytochemical localization of kynurenine aminotransferase II in the rat brain. Soc. Neurosci. Abstr. 31:387.11.

Miller CL, Llenos IC, Dulay JR, Weis S (2006). Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074:25-37.

Miura H, Ando Y, Noda Y, Isobe K, Ozaki N (2011). Long-lasting effects of inescapable-predator stress on brain tryptophan metabolism and the behavior of juvenile mice. Stress 14, 262-272.

Mora F, Segovia G, Del Arco A (2008). Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Res Rev. 58(2):340-53.

Moroni F, Cozzi A, Sili M, Mannaioni G (2012). Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 119(2):133-9. doi: 10.1007/s00702-011-0763-x.

Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E (2005). Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology. 48(6):788-95.

Nicoll RA (2003). Expression mechanisms underlying long-term potentiation: a postsynaptic view. Philos Trans R Soc Lond B Biol Sci. 358(1432):721-6.

Nore´n U, Bjorner A, Sonesson O, and Eriksson L (2006). Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res 85:302–304.

O'Donnell P (2012). Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci. 35(12):1866-70. doi: 10.1111/j.1460-9568.2012.08130.x.

Okuda S, Nishiyama N, Saito H, Katsuki H (1998). 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 70(1):299-307.

Olsson SK, Sellgren C, Engberg G, Landén M, Erhardt S (2012). Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 14, 719-726.

Osborne PG, O'Connor WT, Drew KL, Ungerstedt U (1990). An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and halothane anaesthetised rats. J Neurosci Methods. 34(1-3):99-105.

Pakkanen JS, Jokitalo E, Tuominen RK (2005). Up-regulation of beta2 and alpha7 subunit containing nicotinic acetylcholine receptors in mouse striatum at cellular level. Eur. J. Neurosci. 21, 2681-2691.

Parent A and Hazrati LN (1995). Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 20(1):91-127.

Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM (1997). Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 283(3):1264-75.

Patti L, Raiteri L, Grilli M, Zappettini S, Bonanno G, Marchi M (2007). Evidence that alpha7 nicotinic receptor modulates glutamate release from mouse neocortical gliosomes. Neurochem. Int. 51, 1-7.

Paxinos G and Watson C (1986). The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, San Diego.

Pehrson AL, Bondi CO, Totah NK, Moghaddam B (2013). The influence of NMDA and GABA(A) receptors and glutamic acid decarboxylase (GAD) activity on attention. Psychopharmacology (Berl). 225, 31-39.

Pellicciari R, Venturoni F, Bellocchi D, Carotti A, Marinozzi M, Macchiarulo A, Amori L, Schwarcz R (2008). Sequence variants in kynurenine aminotransferase II (KAT II) orthologs determine different potencies of the inhibitor S-ESBA. ChemMedChem, 3, 1199-1202.

Pellicciari R, Rizzo RC, Costantino G, Marinozzi M, Amori L, Guidetti P, Wu HQ, Schwarcz R (2006). Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem. 1(5):528-31.

Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX (2002). Unconventional ligands and modulators of nicotinic receptors. J Neurobiol. 53(4):479-500.

Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nãsland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000). Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol. 393(1-3):215-22.

Perkins, MN, Stone, TW (1982). An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184-187.

Picciotto MR and Zoli M (2002). Nicotinic receptors in aging and dementia. J Neurobiol. 53(4):641-55.

Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, Devoto P (2002). Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 948, 155-158.

Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R (2012). Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 35, 1605-1612.

Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R (2011). Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology. 36, 2357-2367.

Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010). Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 35, 1734-1742.

Povysheva NV, Zaitsev AV, Rotaru DC, Gonzalez-Burgos G, Lewis DA, Krimer LS (2008). Parvalbumin-positive basket interneurons in monkey and rat prefrontal cortex. J Neurophysiol. 100, 2348-2360.

Prescott C, Weeks AM Staley KJ, Partin KM (2006). Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402(1-2), 108-112.

Quik M, Polonskaya Y, Gillespie A, Jakowec M, Lloyd GK, Langston JW (2000). Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. Comp Neurol. 425(1):58-69.

Radcliffe KA and Dani JA (1998). Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci. 18(18):7075-83.

Ragland JD, Yoon J, Minzenberg MJ, Carter CS (2007). Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. Int Rev Psychiatry. 19(4):417-27.

Rassoulpour A, Wu HQ, Ferre S, Schwarcz R (2005). Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 93(3):762-5.

Rassoulpour A, Wu HQ, Poeggeler B, Schwarcz R (1998). Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Res. 802(1-2):111-8.

Rejdak R, Zarnowski T, Turski WA, Kocki T, Zagorski Z, Zrenner E, Schuettauf F (2003). Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Res. 43(5):497-503.

Rogers RD, Andrews TC, Grasby PM, Brooks DJ, Robbins TW (2000). Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cogn Neurosci. 12(1):142-62.

Rompala GR, Zsiros V, Zhang S, Kolata SM, Nakazawa K (2013). Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes. PLoS One 8, e61278.

Rotaru DC, Barrionuevo G, Sesack SR (2005). Mediodorsal thalamic afferents to layer III of the rat prefrontal cortex: synaptic relationships to subclasses of interneurons. J Comp Neurol. 490, 220-238.

Rozsa E, Robotka H, Vecsei L, Toldi J (2008). The Janus-face kynurenic acid. J. Neural. Transm. 115(8), 1087-1091.

Role LW and Berg DK (1996). Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16(6):1077-85.

Saint-Cyr JA, Taylor AE, Nicholson K (1995). Behavior and the basal ganglia. Adv Neurol. 65:1-28.

Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 305(3):1024-36.

Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX (2002). The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol. 61(5):1222-34.

Sanz B, Exposito I, Mora F (1997). M1 acetylcholine receptor stimulation increases the extracellular concentrations of glutamate and GABA in the medial prefrontal cortex of the rat. Neurochem Res. 22, 281-286.

Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R (2011). Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 37(6):1147-56. doi: 10.1093/schbul/sbq112.

Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009). Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. 14(11):1017-23. doi: 10.1038/mp.2008.28.

Schubert MH, Young KA, and Hicks PB (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530–533.

Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012). Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 13(7):465-77. doi: 10.1038/nrn3257.

Schwarcz R (2004). The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol. 4(1):12-7.

Schwarcz R and Pellicciari R (2002). Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 303(1):1-10.

Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 50(7):521-30.

Schwarcz R, Ceresoli G, Guidetti P (1996). Kynurenine metabolism in the rat brain in vivo. Effect of acute excitotoxic insults. Adv Exp Med Biol. 398:211-9.

Segovia G, Del Arco A, Mora F (1997). Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study. J. Neurochem. 69, 1476-1483.

Séguéla P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993). Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci. 13(2):596-604.

Sharma G and Vijayaraghavan S (2001). Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc. Natl. Acad. Sci. 98, 4148-4153.

Shen JX and Yakel JL (2012). Functional α7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices. J Mol Neurosci. 48, 14-21.

Shepard PD, Joy B, Clerkin L, Schwarcz R (2003). Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28(8):1454-62.

Sher E, Chen Y, Sharples TJ, Broad LM, Benedetti G, Zwart R, McPhie GI, Pearson KH, Baldwinson T, De Filippi G (2004). Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem. 4(3):283-97.

Shink E, Bevan MD, Bolam JP, Smith Y (1996). The subthalamic nucleus and the external pallidum: two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience. 73(2):335-57.

Simpson EH, Kellendonk C, Kandel E (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron. 65(5):585-96. doi: 10.1016/j.neuron.2010.02.014.

Sirinathsinghji DJ and Heavens RP (1987). Stimulation of GABA release from the rat neostriatum and globus pallidus in vivo by corticotropin-releasing factor. Neurosci Lett. 100(1-3):203-9.

Smythe GA, Poljak A, Bustamante S, Braga O, Maxwell A, Grant R, Sachdev P (2003). ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. Adv Exp Med Biol. 527:705- 12

Speciale C and Schwarcz R (1990). Uptake of kynurenine into rat brain slices. J Neurochem. 54(1):156-63.

Spokes EG (1980). Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain. 103(1):179-210.

Stone TW (2001). Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs. 10(4):633-45.

Stone TW (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 45(3):309-79.

Stone TW and Perkins MN (1981). Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 72(4):411-2.

Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP, Doherty JJ, Hudzik T, Johnson E, Mrzljak L, Piser T, Smagin GN, Wang Y, Widzowski D, Smith JS (2009). Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol. 78(7):880-8. doi: 10.1016/j.bcp.2009.07.005.

Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L (2012). Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Curr Top Med Chem. 12(16):1797-806.

Tepper JM, Abercrombie ED, Bolam JP (2007). Basal ganglia macrocircuits. Prog Brain Res. 160:3-7.

Tepper JM and Bolam JP (2004). Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol. 14(6):685-92.

Thomsen MS, Hay-Schmidt A, Hansen HH, Mikkelsen JD (2010). Distinct neural pathways mediate α7 nicotinic acetylcholine receptor-dependent activation of the forebrain. Cereb Cortex. 20(9):2092-102. doi: 10.1093/cercor/bhp283.

Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD (2009). alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology. 56, 1001-1009.

Tian GF, Azmi H, Takano T, Xu Q, Peng W, Lin J, Oberheim N, Lou N, Wang X, Zielke HR, Kang J, Nedergaard M (2005). An astrocytic basis of epilepsy. Nat Med. 11(9):973-81.

Timmerman W and Westerink BH (1997). Brain microdialysis of GABA and glutamate: what does it signify? Synapse. 27(3):242-61.

Timofeeva OA and Levin ED (2011). Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience 195:21-36. doi: 10.1016/j.neuroscience.2011.08.038.

Tseng KY and O'Donnell P (2004). Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci. 24, 5131-5139.

Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ (2004). Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 24(23):5331-5.

Turski WA, Gramsbergen JB, Traitler H, Schwarcz R (1989). Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem. 52, 1629-1636.

Turski WA and Schwarcz R (1988). On the disposition of intrahyppocampally injected kynurenic acid in the rat. Exp Brain Res 71:563-567.

Vecsei L, Plangar I, Szalardy L (2012). Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases? Expert Rev Clin Pharmacol. 5(4):351-3. doi: 10.1586/ecp.12.36.

Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM, Costa E (2007). Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res. 91(1-3):51-61.

Vizi ES (2000). Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev. 52(1):63-89.

Volk DW and Lewis DA (2010). Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci. 4, 485-508.

Voorn P, Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM (2004). Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 27(8):468-74.

Zarei MM, Radcliffe KA, Chen D, Patrick JW, Dani JA (1999). Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience. 88(3):755-64.

Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP (2009). Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 29(3):529-38. doi: 10.1111/j.1460-9568.2008.06594.x.

Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW (1989). Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol. 284(2):314-35.

Wang X, Lippi G, Carlson DM, Berg DK (2013). Activation of α7-containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses. J Neurochem. doi: 10.1111/jnc.12436.

Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 281, 22021-22028.

Wilson CJ (2007). GABAergic inhibition in the neostriatum. Prog Brain Res. 160:91-110.

Wilson CJ (1993). The generation of natural firing patterns in neostriatal neurons. Prog Brain Res. 99:277-97.

Wonnacott S (1997). Presynaptic nicotinic ACh receptors. Trends Neurosci. 20(2):92-8.

Wonnacott S, Barik J, Dickinson J, Jones IW (1997). Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci. 30(1-2):137-40.

Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R (2011). Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011 Jul;68(7):665-74. doi: 10.1001/archgenpsychiatry.

Wonodi I and Schwarcz R (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 36(2):211-8.

Woolf NJ (1991). Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol. 37(6):475-524.

Wu HQ, Okuyama M, Kajii Y, Pocivavsek A, Bruno JP, Schwarcz R Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull. in press.

Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R (2010). The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 40, 204-210.

Wu HQ, Pellicciari R, Bruno JP, Schwarcz R (2008). Endogenous kynurenate modulate extracellular glutamate levels in the rat medial prefrontal cortex. Soc. Neurosci. Abstr. 34, 657.50.

Wu HQ, Rassoulpour A, Schwarcz R (2007). Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm. 114(1):33-41.

Wu HQ, Pellicciari R, Schwarcz R (2006). Bidirectional regulation of extracellular dopamine by endogenous kynurenic acid in the rat medial prefrontal cortex. Soc. Neurosci. Abstr. 32:624.3.

Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, Motomura E, Tanii H, Shiroyama T, Okada M (2009). Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol. 157, 656-665.

Yin HH, Ostlund SB, Balleine BW (2008). Reward-guided learning beyond dopamine in the nucleus accumbens: the integrative functions of cortico-basal ganglia networks. Eur J Neurosci. 28(8):1437-48. doi: 10.1111/j.1460-9568.2008.06422.x.

Yin HH and Knowlton BJ (2006). The role of the basal ganglia in habit formation. Nat Rev Neurosci. 7(6):464-76.

Yu P, Di Prospero NA, Sapko MT, Cai T, Chen A, Melendez-Ferro M, Du F, Whetsell WO Jr, Guidetti P, Schwarcz R, Tagle DA (2004). Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol. 24(16):6919-30.